

**ELENA GABRIELA CHIOREAN, MD, FASCO****1. PERSONAL DATA**

Place of birth: Sebes, Romania  
 Citizenship: USA

**2. EDUCATION**

1983-1987 Baccalaureate, Gheorghe Lazar Mathematics and Physics College, Sibiu, Romania  
 1987-1993 MD, University of Medicine and Pharmacy Cluj-Napoca, Romania

**3. POSTGRADUATE TRAINING**

1994-1995 Laboratory Research-Hematology, University of Michigan, Ann Arbor, MI  
 1995-1996 Internship-Internal Medicine, William Beaumont Hospital, Royal Oak, MI  
 1996-1998 Residency-Internal Medicine, William Beaumont Hospital, Royal Oak, MI  
 1999-2002 Fellowship-Hematology-Oncology, University of Minnesota, Minneapolis, MN

**4. FACULTY POSITIONS HELD**

2002-2004 Assistant Professor of Medicine, Department of Medicine, Division of Hematology-Oncology-Transplantation, University of Minnesota, Minneapolis, MN  
 2004-2006 Assistant Professor of Clinical Medicine, Department of Medicine, Division Hematology-Oncology, Indiana University, Indianapolis, IN  
 2006-2012 Assistant Professor of Medicine, Department of Medicine, Division of Hematology-Oncology, Indiana University, Indianapolis, IN  
 2012-2018 Associate Professor of Medicine, Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA  
 2012-2019 Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center (FHRC), Seattle, WA  
 2018- Professor of Medicine, Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine, Seattle, WA  
 2019- Professor, Clinical Research Division, Fred Hutchinson Cancer Center (FHCC), Seattle, WA  
 2023- Affiliate Investigator, Translational Science and Therapeutics Division, FHCC, Seattle, WA

**5. HOSPITAL POSITIONS HELD**

1998-1999 Attending Physician, Portage View Hospital, Hancock, MI  
 1998-1999 Attending Physician, Keweenaw Memorial Medical Center, Laurium, MI  
 2002-2004 Attending Physician, Fairview University Medical Center, Minneapolis, MN  
 2004-2012 Attending Physician Indiana University Health-University Hospital, Indianapolis, IN  
 2004-2012 Attending Physician, Wishard Health Services Hospital, Indianapolis, IN  
 2004-2012 Attending Physician, Rodebush VA Medical Center, Indianapolis, IN  
 2008-2012 Director, GI Oncology Program, Indiana University Simon Cancer Center, Indianapolis, IN  
 2008-2012 Director, Phase I Program, Indiana University Simon Cancer Center, Indianapolis, IN  
 2010-2012 Co-Director, Multi-disciplinary Pancreatic Cancer Clinic, Indiana University Medical Center, Indianapolis, IN

- 2012- Attending Physician, University of Washington Medical Center (UWMC), Seattle, WA  
 2012- Attending Physician, Fred Hutchinson Cancer Center (FHCC), Seattle, WA  
 2012- Clinical Research Director, GI Oncology Program, UW/FHCC  
 2017- Medical Director, GI Oncology Program, FHCC  
 2022- Deputy Co-Director, Pancreas Cancer Program, FHCC

## 6. HONORS

- 1987 Valedictorian - Mathematics and Physics, Gheorghe Lazar College, Sibiu, Romania  
 1993 Summa cum Laude, Merit Diploma - University of Medicine & Pharmacy, Cluj-Napoca, Romania  
 2001 Fellow Award – American Society of Hematology (ASH)  
 2001 Fellow Award – Mayo Clinic Hematology-Oncology Reviews  
 2006 Danny Danielson Award for Clinical Research – Walther Cancer Institute, Indianapolis, IN  
 2006 ASCO/AACR/NCI/FDA Workshop Award for Accelerating Anticancer Agent Development and Validation Workshop, Bethesda, MD  
 2008 Outstanding Young Clinician Award – Department of Medicine, Indiana University  
 2014 Danny Danielson Translation Innovation Award – Hoosier Cancer Research Network  
 2018 Leaderships that Shapes the Future, University of Washington, Foster School of Business, Seattle, WA  
 2019 Honorary Member, Academy of Medical Sciences, Bucharest, Romania  
 2021 Seattle Metropolitan Top Doctor  
 2022 Seattle Metropolitan Top Doctor  
 2023 Fellow of the American Society of Clinical Oncology (FASCO)  
 2023 Seattle Magazine Top Doctor  
 2023 International Association of Surgeons, Gastroenterologists and Oncologists (IASGO) Teaching Award, Verona, Italy  
 2023 Fellow of the International Association of Surgical Gastrointestinal Oncology (FIASGO)  
 2024 IASGO Teaching Award, Cairo, Egypt  
 2024 APA/CPA/JPA/IAP Hirshberg Symposium Award, Maui, HI  
 2025 Patient Safety Champion, Fred Hutch Cancer Center, Seattle, WA

## 7. BOARD CERTIFICATIONS

- 1998-2008 Diplomate, American Board of Internal Medicine (ABIM)  
 2002-2012 Diplomate, ABIM Subspecialty Board of Hematology  
 2002- Diplomate, ABIM Subspecialty Board of Medical Oncology

## 8. LICENSURE

- 1995-1997 Michigan State Medical License  
 1999-2004 Minnesota State Medical License  
 2004-2013 Indiana State Medical License  
 2012- Washington State Medical License

## 9. DIVERSITY, EQUITY, AND INCLUSION

- 2012- UW/FHCC – Clinical research director GI Oncology program: hire, supervise, guide and promote research staff of diverse races and ethnic backgrounds.  
 2017- UW/FHCC – Clinical director GI Oncology program: lead the recruitment and

- 2019-2022 mentoring of diverse faculty with diverse clinical and research interests  
CRAB/PCRT – Chairman, include a diverse group of community and academic physicians who treat pancreatic cancer patients to participate in investigator initiated and industry led clinical trials.
- 2021- SWOG GI Committee - Vice Chair: promote junior investigators of diverse backgrounds as study champions or participants of working groups; work towards liberalizing inclusion criteria for clinical trials participation to enable patients of diverse social and economic backgrounds to have access and participate in clinical trials; oversee DEI plans for SWOG GI Committee in conjunction with the DEI leadership

## 10. PROFESSIONAL ORGANIZATIONS

- 2000- American Society of Clinical Oncology (ASCO)  
2007- American Association for Cancer Research (AACR)  
2020- European Society of Medical Oncology (ESMO)  
2022- International Association of Surgical Gastrointestinal Oncology (IASGO)

## 11. EDUCATION AND TEACHING RESPONSIBILITIES

### A. Didactic Teaching N/A

### B. Thesis Committee Membership N/A

### C. Advising/Mentorship

Fellows Mentoring (past 5 years)

- 201-2020 Lindsay Hannan, Clinical Assistant Professor, Emory University  
2018-2020 Amy E. Chang, Research Scientist, Eli Lilly, LOXO  
2019-2021 Adam Diehl, Clinical Assistant Professor, University of Washington, FHCC Evergreen  
2023- Sheela Damle, Hematology-Oncology Fellow

Residents Mentoring (past 5 years)

- 2022 Keven Zhang

Faculty Mentoring

- 2015-2021 Kit Wong  
2015- Stacey Cohen  
2016- David Zhen  
2017- Gentry King  
2021- Rachael Safyan  
2022-2024 Jonathan Sham  
2023- Ronan Hsieh

### D. Curriculum and Training Program Development N/A

### E. Other

- 2002-2004 Clinical teaching, students, residents, fellows, APPs, Inpatient Medical Oncology, Hematology and Bone Marrow Transplant, University of Minnesota Medical Center  
2004-2012 Clinical teaching, students, residents, fellows, Inpatient Medical Oncology, Indiana University Medical Center

- 2004-2012 Clinical teaching, students, residents, fellows, Outpatient GI Medical Oncology Clinic, Indiana University Simon Cancer Center
- 2012- Clinical teaching, residents, fellows, Outpatient GI Medical Oncology Clinic, SCCA
- 2012- Clinical teaching, Advanced Practice Providers, Inpatient Medical Oncology/Hematology, UWMC
- 2012- Resident teaching conferences, UWMC
- 2012- Fellows' teaching conferences, FHCRC
- 2012- Faculty discussant, Colorectal Cancer Tumor Conference (weekly)
- 2012- Faculty discussant, Pancreas Cancer Tumor Conference (biweekly)
- 2015-2016 Co-director Clinical Trials / Biostatistics Course UW/FHCRC Hematology-Oncology Fellowship Program
- 2017- Clinical teaching, interns, residents, fellows, Inpatient Medical Oncology, UWMC
- 2023 NCI SWOG Early-Stage Investigator Training Course, Seattle, WA
- 2024 Physician Education Resource (PER) 9<sup>th</sup> Annual School of GI Oncology, Co-Chair, Pasadena, CA
- 2025 PER 10<sup>th</sup> Annual School of GI Oncology, Co-Chair, Pasadena, CA

## 12. EDITORIAL RESPONSIBILITIES

### A. Editorial Boards

- 2011-2013 Editorial Board, Yearbook in Oncology, Gastrointestinal Cancers
- 2015- Editorial Board, Seminars in Oncology
- 2016 Specialty Editor, ASCO Clinical Care Advances - ASCO Annual Report on Progress against Cancer
- 2017-2018 Guest Editor, Seminars in Oncology: Biomarkers Driven and Molecular Targeted Therapies for Gastrointestinal Cancers
- 2017-2022 Editorial Board, Journal of Clinical Oncology
- 2021- Editorial Board, Cancers

### B. Ad hoc Reviewing Responsibilities

- 2012-2025 Reviewer, Journal of Clinical Oncology
- 2012-2025 Reviewer, Clinical Cancer Research
- 2017 Reviewer, Cancer
- 2017 Reviewer, JCO Precision Oncology
- 2018 Reviewer, Clinical Therapeutics and Pharmacology
- 2018-2019 Reviewer, Therapeutic Advances in Medical Oncology
- 2020 Reviewer, Cancer Chemotherapy Pharmacology
- 2020 Reviewer, OncoTarget
- 2021 Reviewer, ESMO Open
- 2021-2023 Reviewer, The Oncologist
- 2022 Reviewer, JAMA Oncology
- 2023 Reviewer, Cancer Research Communications

## 13. SPECIAL RESPONSIBILITIES AND SERVICE

### A. International

- 2010-2013 American Society of Clinical Oncology (ASCO) Scientific Committee, Developmental Therapeutics
- 2011 ASCO, Oral Abstracts Developmental-Experimental Therapeutics Chair
- 2012 ASCO, Poster Discussion Developmental-Experimental Therapeutics Co-Chair
- 2012-2013 ASCO, Scientific Committee Track Leader- Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics

- 2015-2018 ASCO, Scientific Committee Gastrointestinal Cancers (Non-Colorectal)  
2016 ASCO, Educational Session Chair: Localized Pancreatic Cancer Multidisciplinary Management with Incorporation of the ASCO Guidelines
- 2016-2017 ASCO, Scientific Committee Track Leader: GI-Non-Colorectal Cancers  
2018 ASCO, Gastrointestinal Committee (non-CRC) Oral Abstracts-Chair
- 2018-2019 ASCO, Co-Chair Expert Panel Resource Stratified Clinical Practice Guidelines for Late-Stage Colorectal Cancer
- 2020-2021 ASCO IDEA Mentoring Program: Mentoring Early Career Investigator (Brazil)  
2021-2023 ASCO Plenary Series, Scientific Review Committee-Gastrointestinal Cancers Chair
- 2022 ASCO, Clinical Science Symposia – Gastroesophageal, Hepatobiliary, Pancreatic - Co-Chair
- 2023-2024 ASCO Plenary Series, Scientific Review Committee-Gastrointestinal Cancers  
2023- Astellas Pharmaceuticals Steering Committee for Randomized Phase 2 study of Zolbetuximab plus Gemcitabine and nab-Paclitaxel in Metastatic Pancreatic Cancer, Member
- 2023 IASGO 34<sup>th</sup> Congress, Session on Gastrointestinal Neuroendocrine Tumors, Co-Chair, Verona, Italy
- 2023 IASGO 34<sup>th</sup> Congress, Consortium on Pancreas Cancer, Co-Chair, Verona, Italy
- 2024 ASCO, Educational Session: Evolving Treatment Options for Patients with Pancreatic Cancer, Chair
- 2024 ASCO, Career Mentoring with Trainees and Early Career Investigators, Faculty

## B. National

- 2004-2012 Eastern Cooperative Oncology Group (ECOG), Gastrointestinal (GI) Cancers Committee, Member
- 2005-2012 Hoosier Cancer Research Network (HCRN), GI Committee Chair
- 2011-2012 National Cancer Institute (NCI) Gastrointestinal Cancer Steering Committee (GISC) - Pancreatic Cancer Task Force, Junior Member
- 2012- National Comprehensive Cancer Network (NCCN) - Pancreatic Cancer Panel  
2012-2015 HCRN, GI Committee Co-Chair
- 2013- Southwest Oncology Group (SWOG), GI Cancers Committee Member
- 2015-2019 Pancreas Cancer Research Team (PCRT), Vice-Chairman
- 2016-2020 NCCN Framework Initiative Executive Committee: Global Resource Stratification of the NCCN Guidelines for Pancreatic Adenocarcinoma, Medical Oncology Leader
- 2016-2023 NCI GISC: Esophago-Gastric Task Force Member
- 2017-2024 Pancreatic Cancer Research Network (PanCan), Precision Promise Clinical Trial Arm Selection Committee
- 2017- NCCN, Pancreatic Cancer Biomarker Compendium Member
- 2018-2019 SWOG, Co-Chair Gastroesophageal Cancers Sub-Committee
- 2018-2024 Data Safety and Monitoring Board (DSMB): VICC MD 1854 A pilot trial of Ifetroban, a thromboxane A2 receptor antagonist, in patients with malignant solid tumors at high risk of metastatic recurrence; Chair (Dr Ingrid Mayer, PI, Vanderbilt University)
- 2019-2021 SWOG, Co-Chair Pancreatic Cancers Sub-Committee
- 2019- NCI GISC Pancreatic Cancer Task Force Member
- 2019-2021 Department of Veterans Affairs Study Section – VA Merit BLR&D/ CSR&D Peer Review Cancer Research Panel
- 2020- SWOG Clinical Trials Partnerships - Scientific Advisory Board, Member
- 2020- NCCN Value Pathways Task Force, Member

2020-2022	FDA, Oncology Center of Excellence: Pancreas Cancer Clinical Trials Working Group
2021	NCI GISC: Pancreatic Cancer Task Force Vice-Chair
2021	NCCN Guidelines for Patients: Pancreatic Cancer, medical oncologist leader
2021-	NCCN Guidelines: Pancreatic Cancer Chemotherapy Templates, leader
2021-2022	Colorectal Cancer Alliance: Biomarker Think Tank Committee, member
2021-	SWOG GI Cancers Committee, Vice-Chair
2021-	NCCN Guidelines: Ampullary Cancers Panel, Leader
2021-	V Foundation Study Section - Peer Review Cancer Research Panel
2022-	American College of Radiology (ACR) Appropriateness Criteria for Pancreatic Cancer, Member
2022-	NCI Pancreas Cancer Task Force, Radiation Therapy Working Group; Co-Chair Novel radiosensitizers committee
2023	Lustgarten Foundation Study Section- Equity, Accessibility and Diversity Project Grants in Pancreatic Cancer
2023-2026	Pancreatic Cancer Action Network Scientific Advisory Board, Member
2023-2024	Lustgarten Foundation-AACR Pancreatic Cancer Research Grants Scientific Review Committee Panel
2023-2025	AACR Daniel D van Hoff Award for Outstanding Contributions to Education and Training in Cancer Research Awards Committee, Member
2024	9 <sup>th</sup> Annual School of Gastrointestinal Oncology (SOGO): Multidisciplinary Approach to GI Cancers Education, Co-Chair
2024	ASCO Annual Meeting, Chair, Education Session: Importance of Multidisciplinary Care for Individuals with Pancreatic Cancer, Chicago, IL
2024	V Foundation Study Section: 2024 Translational Grant Awards Review Panel
2024-2025	Lustgarten Foundation-AACR Pancreatic Cancer Research Grants Scientific Review Committee Panel
2025	10 <sup>th</sup> Annual School SOGO, Co-Chair

### C. Local

2012-	UW/FHCRC/SCCA GI Oncology Program -Clinical Research Director
2012-	UW/FHCRC/SCCA GI Oncology Leadership Committee
2012-	FHCRC-GI Cancer Etiology, Prevention Consortium Member
2012-	UW/FHCRC/SCCA Clinical Research Directors Advisory Committee
2012-	SCCA Research Network Committee
2012-	Pancreas Cancer Working Group
2013	Pancreas Cancer Pathways Guidelines Committee
2013-2017	Faculty Promotion Committee, Chair-Dr. Veena Shankaran, Dr. Andrew Coveler, Dr. William Harris
2014	GI Cancers Symposium UW/FHCRC/SCCA, Co-Chair
2014-2015	Scientific Review Committee (SRC) FHCRC, Co-chair
2014-2019	GI Oncology Faculty Search Committee, Chair
2014-	Solid Tumor Translational Research (STTR), FHCRC, Pancreas and Colorectal Cancers Research Groups member
2015-2020	FHCRC Scientific Review Committee B, Chair
2016	Advances and Current Management of GI Cancers Symposium UW/FHCRC/SCCA, Co-Chair
2017-2019	Faculty Promotion Committee- Dr. Stacey Cohen, Dr. Jonathan Grim
2018-2019	Faculty Mentoring Committee- Dr. Ryan Lynch, Dr. Kit Wong
2018-	Chair, Data Safety and Monitoring Board (DSMB) multi-institutional ADAM trial-Dr. Shailender Bhatia UW/FHCRC

2019- Co-Chair UW/FHCC GI Oncology Retreats-biannual  
 2020-2021 Faculty Promotion committee- Dr Veena Shankaran  
 2020-2021 Co-Chair Seattle Cancer Care Alliance CMO Search Committee  
 2022- Deputy Co-Director, FHCC STTR Pancreas Cancer program  
 2022- Faculty Mentoring Committee Chair- Dr Gentry King, Dr Rachael Safyan  
 2022-2025 UW Department of Medicine Clinical and Affiliate Appointment and Promotion  
 Committee (CAAP), Member  
 2023- Faculty Mentoring Committee Chair- Dr Ronan Hsieh  
 2024- Chair, UW/FHCC Phase 1 Program Leader Search Committee  
 2024-2025 Faculty Promotion Committee - Dr Gentry King  
 2025 Cancer Consortium Pilot Award Committee

#### 14. CLINICAL ACTIVITIES

2012-2025 4 half days/week GI Medical oncology clinics, including Phase 1 clinical trials  
 1 half day/month multidisciplinary pancreas cancer clinic (cFTE 0.40)  
 2025- 3 half days/week GI Medical Oncology clinic, including Phase 1 clinical trials  
 1 half day/month multidisciplinary clinic pancreas cancer clinic (cFTE 0.30)  
 2012- 2 weeks/year inpatient oncology attending (cFTE 0.05)

#### 15. RESEARCH FUNDING

##### A. Current

2017- Sponsor: NIH/NCI  
 UG1 CA233328  
 Title: Fred Hutchinson Cancer Center as Lead Academic Participating Site  
 (UG1)  
 Total Costs: \$19,830,301 (0.12 CM)  
 Role: Co-Investigator (PI – Yu)

2019- Sponsor: Lilly  
 Title: Phase 2 study of the CDK4/6 inhibitor abemaciclib in advanced and  
 refractory well-differentiated gastroenteropancreatic neuroendocrine tumors  
 (GEP NETs) (*investigator-initiated study*)  
 Total costs: \$499,868  
 Role: Co-PI (PI: Zhen DB)

2021- Sponsor: NIH/NCI  
 Title: ECOG-ACRIN EA2192: a randomized phase II double blind study of  
 olaparib versus placebo following adjuvant chemotherapy in patients with  
 resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2  
 mutation  
 Role: SWOG study champion (PIs, Reiss-Binder K/Kasi A)

2021- Sponsor: Lonza/SU2C  
 Title: Phase I study of autologous transgenic T cells expressing high affinity  
 mesothelin-specific T-cell receptor (TCR-T<sub>MSLN</sub>) in patients with metastatic  
 pancreatic ductal adenocarcinoma (*investigator-initiated study*)  
 Total costs: \$420,795  
 Role: PI

2021- Sponsor: NIH/NCI  
 Title: SWOG S2012, randomized phase 2/3 trial of first line  
 platinum/etoposide with or without atezolizumab in patients with poorly  
 differentiated extrapulmonary small cell neuroendocrine carcinomas  
 (*investigator-initiated study*)

- 2021- Total costs: \$52,000  
Role: Co-Chair (PI, Zhen DB)  
Sponsor: NIH/NCI  
U10 CA180888  
SWOG Network Group Operations Center of the NCTN  
Main grant: \$11,831,369 (0.60 CM)
- 2022- Role: Vice Chair, GI Cancers Committee (SWOG Chair, Blanke C)  
Sponsor: Erasca, Inc.  
Title: ERAS-007-003 A Phase 1b/2 Study of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Advanced Gastrointestinal Malignancies (HERKULES 3)  
Total Costs: \$1,879,867  
Role: Local PI
- 2022- Sponsor: Merck Sharp & Dohme Corp.  
Title: MK4280 007 CRC A Phase 3 study of MK-4280A (co-formulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer  
Total costs: \$4,269,604  
Role: Local PI
- 2022- Sponsor: Novartis Pharmaceuticals Corporation  
Title: NIS793B12301 A randomized, double-blind, phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma  
Total Costs: \$1,229,888  
Role: Local PI
- 2023- Sponsor: Mirati/Bristol Meyers Squibb  
Title: A phase 1/2 multiple expansion cohort trial of MRTX1133 in patients with advanced solid tumors harboring a *KRAS* G12D mutation  
Total Costs: \$1,571,433  
Role: Local PI
- 2023- Sponsor: Mirati/Bristol Meyers Squibb  
Title: A phase 1/2 multiple expansion cohort trial of the SOS1 inhibitor MRTX0902 in patients with advanced solid tumors harboring mutations in the *KRAS*-MAPK pathway  
Total Costs: \$1,079,340  
Role: Local PI
- 2023- Sponsor: Affini-T Pharmaceuticals  
Title: Phase I study of autologous CD8+ and CD4+ Transgenic T cells expressing high affinity KRASG12V mutation-specific T cell receptors in patients with advanced or metastatic cancers with *KRAS* G12V mutations (*investigator-initiated trial*)  
Total Costs: \$10,208,681  
Role: PI
- 2023-2027 Sponsor: V Foundation  
Title: Targeting CDK7 in basal subtype pancreatic ductal adenocarcinoma  
Total Costs: \$800,000  
Role: Co-I (PI: Sita Kugel, PhD)
- 2024- Sponsor: Genentech  
Title: A phase II, open label, multicenter randomized study of the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and mFOLFIRINOX

versus mFOLFIRINOX alone in patients with resected pancreatic ductal adenocarcinoma

Total Costs: \$689,291

Role: Local PI

2024- Sponsor: Affini-T Pharmaceuticals  
 Title: Phase I study of autologous CD8+ and CD4+ engineered T cells receptor T cells in subjects with advanced or metastatic solid tumors  
 Total Costs: \$1,004,175

Role: Local PI

2024- Sponsor: BioAtla  
 Title: An open-label, multicenter, phase 1 study evaluating the safety, pharmacokinetics and efficacy of BA3182, a bispecific epithelial cell adhesion molecule (EPCAM)/CD3 antibody in patients with advanced adenocarcinoma  
 Total Costs: \$1,213,680

Role: Local PI

### **B. Pending**

2025- Sponsor: Revolution Medicines  
 Title: A Platform Study of RAS(ON) Inhibitor Combinations in Patients with Gastrointestinal Solid Tumors  
 Role: Local PI

2025- Sponsor: Revolution Medicines  
 Title: A Phase 3 multicenter, open-label, randomized study of RMC-6236 versus investigator's choice of standard of care therapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma

Role: Local PI

2025- Sponsor: Lilly/LOXO  
 Title: A Phase 1a/1b trial of LY3962673 in participants with *KRAS* G12D-mutant solid tumors

Role: Local PI

2025- Sponsor: Sapience  
 Title: A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects with Selected Advanced Unresectable and Metastatic Solid Tumors

Role: Local PI

2025- Sponsor: NIH/NCI  
 Title: SWOG S2433, Randomized phase 3 study of second line chemotherapy with or without panitumumab for locally advanced or metastatic *KRAS* wild type pancreatic adenocarcinoma (*investigator-initiated study*)

Role: Co-Chair (PI, Safyan RA)

2025- Sponsor: Sanofi  
 A Phase 1/2, open label, first-in-human, dose escalation and expansion study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity of SAR445877 administered as monotherapy or in combination with other anticancer therapies in adults with advanced solid tumors

Role: Local PI

### **C. Past**

2000-2002 Sponsor: NIH  
 Title: National Research Service Award 5 T32 HL07062

- Total Costs: \$77,496  
 Role: Training Hematology-Oncology Fellow  
 2004-2007 Sponsor: Threshold  
 Title: A phase I/II dose-escalation study of the safety, efficacy and pharmacokinetics of glufosfamide in combination with gemcitabine in advanced solid tumors and pancreatic adenocarcinoma  
 Total costs: \$144,450
- 2004-2010 Role: Local PI  
 Sponsor: Roche/Pfizer/Hoosier Oncology Group  
 Title: Phase II multi-institutional trial of preoperative capecitabine plus irinotecan followed by combined modality capecitabine and radiation for locally advanced rectal cancer (GI03-53) (*investigator-initiated study*)  
 Role: PI
- 2005-2006 Sponsor: GPC  
 Title: A phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory non-hematologic cancer  
 Role: Local PI
- 2005-2006 Sponsor: GPC  
 Title: A phase I study of the effects of hepatic impairment on the pharmacokinetics and safety of satraplatin in patients with refractory non-hematologic cancer  
 Role: Local PI
- 2005-2007 Sponsor: Indiana University Pilot Studies Grant  
 Title: Pilot study using neoadjuvant chemoradiotherapy and an EGFR-tyrosine kinase inhibitor, erlotinib, for potentially resectable pancreatic cancer (IUCRO-0130) (*investigator-initiated study*)  
 Total costs: \$25,000  
 Role: Co-PI (Chiorean, Cardenes)
- 2005-2008 Sponsor: ImClone  
 Title: Phase I study of every other week anti-vascular endothelial growth factor receptor 2 (VEGFR-2) monoclonal antibody IMC-1121B in patients with advanced solid tumors who have not responded to standard therapy  
 Total costs: \$229,781  
 Role: Local PI
- 2005-2006 Sponsor: Amgen  
 Title: Phase 2 trial of AMG706 for patients with gastrointestinal stromal tumors  
 Role: Local PI
- 2005-2011 Sponsor: NIH  
 Title: ECOG 5202, a randomized phase II study comparing 5-FU, leucovorin and oxaliplatin versus 5-FU, leucovorin, oxaliplatin and bevacizumab in patients with stage II colon cancer at high risk for recurrence to determine the prognostic value of molecular markers  
 Role: Local PI
- 2006-2007 Sponsor: Wyeth  
 Title: Phase I dose-escalation study of oral SKI-606 in subjects with advanced solid tumors and pancreatic cancer  
 Role: Local PI
- 2006-2008 Sponsor: Threshold  
 Title: Phase I dose escalation trial of 2-deoxy-D-glucose (2DG) alone and in combination with docetaxel in subjects with advanced solid malignancies  
 Total costs: \$134,000

- 2006-2008 PI: Local PI  
Sponsor: Adnexus  
Title: A Phase 1, escalating dose study of CT-322, a VEGFR-2 antagonist, as monotherapy in patients with advanced solid tumors and non-Hodgkin's lymphoma  
Role: Local PI
- 2006-2010 Sponsor: Sanofi-Aventis/OSI/Hoosier Oncology Group  
Title: Phase II multi-institutional trial of erlotinib in combination with docetaxel in advanced hepatocellular and biliary tract carcinomas (GI06-101) (*investigator-initiated study*)  
Total costs: \$160,000  
Role: PI
- 2006- 2010 Sponsor: Glaxo SmithKline  
Title: An open-label, two-period, randomized, crossover study to evaluate the effect of food on the pharmacokinetics of single doses of pazopanib in cancer patients  
Total costs: \$263,268  
Role: Local PI
- 2006-2009 Sponsor: Glaxo SmithKline  
Title: An open-label, Phase 1b study to assess the long term safety profile of effect of pazopanib in cancer patients  
Total costs: \$119,224.00  
Role: Local PI
- 2006-2008 Sponsor: Pfizer  
Title: Phase I safety and pharmacokinetic study of SU011248 and capecitabine in patients with advanced solid tumors  
Role: Local PI
- 2006-2011 Sponsor: ImClone  
Title: Phase 1 study of IMC-3G3, an IgG1 monoclonal antibody targeting PDGFR $\alpha$  in patients with advanced solid malignancies  
Total costs: \$154,465  
Role: Local PI
- 2006-2011 Sponsor: NCI  
Title: ECOG 4203; phase II study of treatment selection based upon tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer  
Role: Local PI
- 2006-2010 Sponsor: NCI  
Title: ECOG 5203; a phase II study to evaluate overall response rate of BAY 43-9006 (Sorafenib) combined with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma  
Role: Local PI
- 2006-2011 Sponsor: Bayer/Onyx and Indiana University Pilot Studies Grant  
Title: Phase I and pharmacodynamic study of gemcitabine with novel Raf kinase-vascular phase endothelial growth factor receptor inhibitor sorafenib (BAY 43-9006) and radiotherapy in patients with locally advanced unresectable pancreatic adenocarcinoma (IUCRO-0155) (*investigator-initiated study*)  
Total costs: \$140,000  
Role: PI
- 2006-2011 Sponsor: NCI

- Title: N0147, a randomized phase III trial of oxaliplatin (OXAL) plus 5-fluorouracil (5-FU)/leucovorin (CF) with or without cetuximab (C225) after curative resection for patients with stage III colon cancer  
Role: Local PI
- 2006-2013 Sponsor: Novartis/ Pfizer/ Bristol-Myers Squibb/ Hoosier Oncology Group  
Title: Phase I/randomized phase II multi-institutional study of second line therapy with irinotecan in combination with cetuximab with or without RAD001, an mTOR inhibitor for patients with metastatic colorectal cancer (GI05-102) (*investigator-initiated study*)  
Total costs: \$1,000,000  
Role: PI
- 2007 Sponsor: Collaborations in Biomedical Research Pilot Grant - Indiana University/Purdue University  
Title: Metabolomics-based detection of colon cancer (*investigator-initiated study*)  
Total costs: \$50,000  
Role: Co-PI (Raftery, Chiorean)
- 2007-2009 Sponsor: Methygene  
Title: Phase I/II study of MGCD0103 in combination with gemcitabine in patients with solid tumors/pancreatic cancer  
Role: Local PI
- 2007-2011 Sponsor: Indiana University Simon Cancer Center Translational Research Acceleration Collaboration (TRAC) Grant  
Title: Pilot study of genomic/ metabolomic/ epigenetic analysis in pancreatic adenocarcinoma (*investigator-initiated study*)  
Total costs: \$76,000  
Role: PI
- 2007-2010 Sponsor: Novartis  
Title: A randomized double-blinded placebo-controlled, multicenter phase III study of patients with advanced carcinoid tumor receiving Sandostatin LAR and RAD001 10 mg/d or Sandostatin LAR and placebo  
Role: Local PI
- 2007-2011 Sponsor: Lilly  
Title: Pharmacokinetic study of enzastaurin in cancer patients with varying degrees of hepatic dysfunction  
Total costs: \$132,146  
Role: Local PI
- 2007-2011 Sponsor: Semafore  
Title: Phase I open label, safety, pharmacokinetic and pharmaco-dynamic dose escalation study of SF1126, a PI3 kinase (PI3K) inhibitor, given twice weekly by iv infusion to patients with advanced or metastatic tumors  
Total costs: \$659,918  
Role: Local PI
- 2007-2011 Sponsor: Takeda  
Title: Multicenter, open-label, noncomparative phase I clinical and pharmacokinetic study of oral TAK-285 in patients with advanced cancer  
Total costs: \$329,562  
Role: Local PI
- 2007-2012 Sponsor: Enzon  
Title: Phase I, multicenter, open-label, dose-escalation study evaluating the safety and tolerability of EZN-2968, a locked nucleic acid antisense

- oligonucleotide against hypoxia-inducible factor-1 $\alpha$  (anti-HIF-1 $\alpha$  LNA AS-ODN) in adult patients with advanced solid tumors or lymphoma  
Total costs: \$416,578  
Role: Local PI
- 2007-2011 Sponsor: NIH  
Title: ECOG 3205, phase II trial of cetuximab plus cisplatin, 5-fluorouracil and radiation in immunocompetent patients with anal carcinoma  
Role: Local PI
- 2007-2013 Sponsor: Genentech and Bayer/ Onyx, IU Simon Cancer Center Pilot Study Grant/ CTSI  
Title: Phase I dose-escalation drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with solid tumors (*investigator-initiated study*)  
Total costs: \$263,605  
Role: PI
- 2008 Sponsor: GlaxoSmithKline  
Title: Phase I first-in-human study of AKT Inhibitor GSK690693 in patients with solid tumors  
Total costs: \$15,593  
Role: Local PI
- 2008-2009 Sponsor: Sanofi-Aventis  
Title: Phase 2 randomized trial of 5-FU versus larotaxel as second line treatment for patients with pancreatic cancer  
Total costs: \$369,800  
Role: Local PI
- 2008-2009 Sponsor: Infinity  
Title: A Phase 3, randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of IPI-504 in patients with metastatic and/or unresectable gastro-intestinal stromal tumors following failure of at least Imatinib and Sunitinib  
Role: Local PI
- 2008-2010 Sponsor: NIH/R21  
Title: Critical evaluation of lysophosphatidylcholines (LPCs) markers for colorectal cancer  
Total costs: \$308,000  
Role: Co-Investigator
- 2008-2010 Sponsor: Novartis  
Title: A randomized double-blind phase III study of RAD001 plus best supportive care versus placebo plus best supportive care in the treatment of patients with advanced pancreatic neuroendocrine tumor (NET)  
Role: Local PI
- 2008-2011 Sponsor: Department of Defense (DOD)  
Title: "Warfighter cancer care engineering" (W81XWH-08-1-0065)-Project A 14594.1a Cancer care engineering of colorectal cancer - OMCs Pilot Study (*investigator-initiated study*)  
Total costs: \$1,750,287  
Role: PI project A
- 2008-2012 Sponsor: Threshold  
Title: Phase I, multicenter, open-label, dose-escalation study of the safety, pharmacokinetics and anti-tumor activity of TH-302 in patients with advanced solid tumors

- Total costs: \$336,591  
 Role: Local PI  
 2008-2012 Sponsor: Threshold  
 Title: Phase 1/2, multicenter, dose-escalation study to determine the safety, efficacy and pharmacokinetics of TH-302 in combination with A) gemcitabine or B) docetaxel or C) pemetrexed in subjects with advanced solid tumors  
 Total costs: \$252,803  
 Role: Local PI  
 2008-2012 Sponsor: Pfizer  
 Title: Phase 1/2 study single arm, open label study of CP-870,893 in combination with gemcitabine in patients with chemotherapy naïve surgically incurable pancreatic cancer  
 Total costs: \$1,221,929  
 Role: Local PI  
 2009-2010 Sponsor: Proacta  
 Title: A randomized phase I/II, multi-center, open label trial of PR104 and Sorafenib in patients with advanced hepatocellular carcinoma  
 Total costs: \$243,305  
 Role: Local PI  
 2009-2010 Sponsor: Amgen  
 Title: A phase 1b open-label dose escalation study of AMG 655 in combination with AMG 479 in subjects with advanced, refractory solid tumors  
 Total costs: \$130,060  
 Role: Local PI  
 2009-2010 Sponsor: Abbott  
 Title: A phase 1 single dose study evaluating the oral bioavailability and pharmacokinetics of multiple formulations of ABT-263 in subjects with cancer  
 Total costs: \$133,757  
 Role: Local PI  
 2009-2011 Sponsor: Newlink Genetics  
 Title: A phase II study of hyper-acute pancreatic vaccine in combination with chemotherapy and chemoradiotherapy in subjects with surgically resected pancreatic cancer  
 Total costs: \$77,076  
 Role: Local PI  
 2009-2011 Sponsor: Celgene  
 Title: Phase I study to assess the safety, pharmacokinetics and potential effects of Amrubicin on the QT/QTc interval in cancer patients with advanced solid tumors  
 Total costs: \$156,766  
 Role: Local PI  
 2009-2011 Sponsor: Tigris  
 Title: A phase 1 study of GGTI-2418 (geranylgeranyl transferase I inhibitor) in patients with advanced solid tumors  
 Total costs: \$417,025  
 Role: Local PI  
 2009-2012 Sponsor: Lilly  
 Title: A phase 1b study of LY573636-sodium in combination with Alimta (Pemetrexed) in patients with solid tumors  
 Role: Local PI  
 2009-2012 Sponsor: Regeneron

- Title: A phase I, multiple-dose study of the safety and tolerability of REGN421 (Notch 1 inhibitor) administered every 3 weeks in patients with advanced solid malignancies  
Role: Local PI
- 2009-2012 Sponsor: Abraxis-Celgene  
Title: A randomized phase III study of weekly ABI-007 plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas  
Role: Local PI
- 2009-2012 Sponsor: NewLink Genetics  
Title: A phase III study of chemotherapy and chemoradiotherapy with or without HyperAcute®-pancreatic cancer vaccine in subjects with surgically resected pancreatic cancer  
Total costs: \$85,715  
Role: Local PI
- 2009-2016 Sponsor: Walther Cancer Institute; Indiana University; Novartis, Amgen  
Title: Phase I study of dual insulin-like growth factor receptor and mTOR inhibition with AMG 479 plus RAD001 in patients with refractory solid tumors (*investigator-initiated study*)  
Total costs: \$323,655  
Role: PI
- 2010-2012 Sponsor: Department of Defense (DOD)  
Title: Warfighter Cancer Care Engineering Phase II (W81XWH-08-1-0065) (*investigator-initiated study*)  
Total costs: \$2,150,000  
Role: Co-Investigator
- 2010-2012 Sponsor: Clarian Value Grant/Indiana University  
Title: Usefulness of DCE-MRI in evaluating response of hepatic metastases from colorectal cancer to anti-angiogenic therapy  
Total costs: \$80,000  
Role: Co-Investigator
- 2010-2012 Sponsor: Celgene  
Title: Open-label dose-escalation study with lenalidomide and sorafenib for the treatment of hepatocellular carcinoma (*investigator-initiated study*)  
Role: Co-PI (Chiorean, Vinayek)
- 2010-2012 Sponsor: Threshold  
Title: A randomized cross-over phase 2 study of the safety and efficacy of two dose levels of TH-302 in combination with gemcitabine compared with gemcitabine alone in previously untreated patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma. TH-CR-404  
Total costs: \$300,575  
Role: Local PI
- 2010-2012 Sponsor: ImClone  
Title: Phase I study of the anti-Ron receptor monoclonal antibody IMC-RON8 in patients with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available  
Total costs: \$ 113,006  
Role: Local PI
- 2011-2012 Sponsor: Intellikine-Millennium  
Title: Phase 1, open-label, dose escalation study of oral administration of single agent INK128 in subjects with advanced solid malignancies followed by an expansion in subjects with measurable disease

- 2011-2012 Role: Local PI  
Sponsor: ImClone-Lilly  
Title: Phase 1 study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in patients with advanced solid tumors that no longer respond to standard therapy or for whom no standard therapy is available
- 2011-2012 Role: Local PI  
Sponsor: Lilly  
Title: Randomized phase 2 study of LY2157299 in patients with hepatocellular carcinoma who have had disease progression on sorafenib or are not eligible to receive sorafenib
- 2011-2012 Role: Local PI  
Sponsor: Tracon  
Title: An open label phase 1b dose escalation study of TRC105 combined with standard dose bevacizumab for advanced solid tumors
- 2011-2012 Role: Local PI  
Sponsor: Incyte  
Title: A randomized phase 2 study of ruxolitinib efficacy and safety in combination with capecitabine for subjects with recurrent or treatment refractory metastatic pancreatic cancer (The RECAP trial)
- 2011-2012 Role: Local PI  
Sponsor: Gilead  
Title: A phase 2 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-6624 combined with FOLFIRI as second line treatment for metastatic KRAS mutant colorectal adenocarcinoma that has progressed following a first line oxaliplatin- and fluoropyrimidine-containing regimen
- 2011-2012 Role: Local PI  
Sponsor: NCI  
Title: CALGB 80702, a phase III trial of 6 versus 12 treatments of adjuvant FOLFOX plus celecoxib or placebo for patients with resected stage III colon cancer
- 2012 Role: Local PI  
Sponsor: Pancreatic Cancer Signature Center/IUSCC Pilot Grant  
Title: Phase Ib study of neo/adjuvant vismodegib (GDC-0449), a hedgehog pathway signaling inhibitor in combination with radiotherapy and with or without gemcitabine for patients with resectable pancreatic cancer (*investigator-initiated study*)  
Total costs: \$49,688
- 2013-2015 Role: Co-PIs (Chiorean, Xie)  
Sponsor: Spectrum Pharmaceuticals  
Title: A phase 2 study of SPI-1620 in combination with docetaxel as a second-line treatment for patients with advanced biliary cancer  
Total costs: \$160,604
- 2013-2015 Role: Local PI  
Sponsor: Genentech  
Title: Steam (Sequencing Triplet with Avastin and Maintenance): Folfxiri/ bevacizumab regimens (concurrent and sequential) vs. Folfx/ bevacizumab in first-line metastatic colorectal cancer  
Total costs: \$103,393
- 2014-2015 Role: Local PI  
Sponsor: Prism Pharmaceuticals

- Title: Phase Ib multicenter, cohort dose escalation trial to determine the safety, tolerance and preliminary antineoplastic activity of gemcitabine administered in combination with continuous intravenous doses of PRI-724, a CBP/ B-Catenin inhibitor, to patients with advanced or metastatic pancreatic adenocarcinoma eligible for second-line therapy after failing first-line therapy with FOLFIRINOX (or FOLFOX)  
 Total costs: \$412,822  
 Role: Local PI
- 2014-2016 Sponsor: Incyte Pharmaceuticals  
 Title: A randomized, double-blind, phase 3 study of ruxolitinib or placebo in combination with capecitabine in subjects with advanced or metastatic adenocarcinoma of the pancreas who have failed or are intolerant to first-line chemotherapy  
 Total costs: \$380,949  
 Role: Local PI
- 2014-2016 Sponsor: Celgene  
 Title: A phase 3 multicenter, open-label, randomized study of nab-paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma  
 Total costs: \$315,757  
 Role: Local PI
- 2015-2016 Sponsor: New Link Genetics  
 Title: A phase 2 study of neoadjuvant chemotherapy followed by stereotactic body radiation therapy (SBRT) with Algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable pancreatic cancer  
 Total costs: 252,033  
 Role: Local PI
- 2015-2016 Sponsor: BMS/F-Star Pharmaceuticals  
 Title: Phase I multiple ascending dose study of anti-HER2 Fcab FS102 in breast, gastric, and other solid tumors  
 Total costs: \$467,409  
 Role: Local PI
- 2013-2017 Sponsor: NCI/Cancer Center Consortium Grant (CCSG)  
 Title: DNA repair pathway assessment by BROCA/homologous recombination deficiency (BROCA-HR) assay in pancreatic adenocarcinoma  
 Total costs: \$32,000  
 Role: PI
- 2017-2018 Sponsor: ACCRU/Bayer  
 Title: Regorafenib dose optimization study (ReDOS); a phase 2 randomized study of lower dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer (*investigator-initiated study*)  
 Total costs: \$114,097  
 Role: Translational PI
- 2014-2018 Sponsor: NCI/SWOG  
 Title: SWOG1313, a phase Ib/II randomized study of modified FOLFIRINOX + pegylated recombinant human hyaluronidase (PEGPH20) versus modified FOLFIRINOX alone in patients with good performance status metastatic pancreatic adenocarcinoma  
 Role: Local PI
- 2017-2018 Sponsor: Incyte, Corporation

- A Phase 1/2 study exploring the safety, tolerability, effect on the tumor microenvironment, and efficacy of azacitidine in combination with pembrolizumab and epacadostat in subjects with advanced solid tumors  
 Role: Local PI  
 Total costs: \$539,979
- 2017-2018 Sponsor: Lilly  
 An adaptive, open-label, randomized phase 2 study of abemaciclib as a monotherapy and in combination with other agents versus choice of standard of care (gemcitabine or capecitabine) in patients with previously treated metastatic pancreatic ductal adenocarcinoma  
 Total costs: \$525,617.11  
 Role: Global PI
- 2015-2018 Sponsor: Celgene  
 Title: A phase 1, open-label, multicenter, safety study of nivolumab (BMS-936558) in combination with nab-paclitaxel plus or minus gemcitabine in pancreatic cancer, nab-paclitaxel/carboplatin in stage IIIb/IV non-small cell lung cancer or nab-paclitaxel in recurrent metastatic breast cancer  
 Total costs: \$1,132,408  
 Role: Local PI
- 2013-2019 Sponsor: NCCN  
 Title: A phase I/II study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors (PNET)  
 Total costs: \$43,200  
 Role: Local PI
- 2013-2019 Sponsor: NCI/CTSU  
 Title: PROSPECT N1048: A phase II/III trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision  
 Role: Local PI
- 2015-2024 Sponsor: Ignyta/ROCHE  
 Title: RDX-101-02 A phase 1/2A, multicenter, open-label study of oral entrectenib (RXDX-101) in adult patients with locally advanced or metastatic cancer confirmed to be positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alterations  
 Total costs: \$483,228  
 Role: Local PI
- 2015-2024 Sponsor: Boehringer-Ingelheim  
 Title: Phase I/Ib multi-institutional study of afatinib (BIBW 2992), an irreversible EGFR/HER2 inhibitor in combination with capecitabine for advanced solid tumors and pancreatobiliary tract cancers (*investigator-initiated study*)  
 Total costs: \$398,996  
 Role: PI
- 2016-2019 Sponsor: NCI, SU2C, CITN  
 Title: Phase I study of neo-adjuvant RO7009789 alone or neo-adjuvant RO7009789 plus nab-paclitaxel and gemcitabine followed by adjuvant RO7009789 plus nab-paclitaxel and gemcitabine for patients with newly diagnosed resectable pancreatic carcinoma  
 Total costs: \$42,000.00  
 Role: Local PI
- 2016-2019 Sponsor: NIH/NCI

- Title: SWOG S1513, randomized phase II study of 2<sup>nd</sup> line therapy with FOLFIRI with and without PARP inhibitor veliparib (ABT888) in metastatic pancreatic cancer (*investigator-initiated study*)  
 Role: National PI
- 2016-2019 Sponsor NIH/NCI  
 BIQSFP: Biomarkers correlatives of DNA repair in SWOG S1513 randomized phase II study of FOLFIRI with or without veliparib in patients with metastatic pancreatic cancer  
 Total costs: \$550,000  
 Role National PI
- 2016-2023 Sponsor: Stemline  
 Title: STML-801-0115 A phase 1 study of SL-801, a reversible inhibitor of nuclear export, in patients with advanced solid tumors  
 Total costs: \$510,417  
 Role: Local PI
- 2018-2022 Sponsor: CRAB/PCRT, Merck and Halozyme  
 Title: PCRT16-001 phase 2 multi-institutional study of PEGPH20 and pembrolizumab (MK-3475) for patients with hyaluronic acid high (HA-High) previously treated metastatic pancreatic adenocarcinoma (*investigator-initiated study*)  
 Total costs: \$1,500,000  
 Role: PI
- 2019 Sponsor: Bristol-Myers Squibb Company  
 A phase 2 study of cabiralizumab (BMS986227, FPA008) administered in combination with nivolumab (BMS936558) with and without chemotherapy in patients with advanced pancreatic cancer  
 Role: Local PI
- 2019-2021 Sponsor: MacroGenics, Inc.  
 Title: Phase 1b/2 open label, dose escalation study of MGD007, a humanized gpA33 x CD3 DART protein in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory metastatic colorectal carcinoma.  
 Total costs: \$710,911  
 Role: Local PI
- 2019-2022 Sponsor: Clovis  
 Title: LODESTAR: A phase 2 multicenter, open-label study of rucaparib as treatment for solid tumors associated with deleterious mutations in homologous recombination repair genes.  
 Total costs: \$482,680  
 Role: Local PI
- 2018-2022 Sponsor: Merck Sharp & Dohme Corp.  
 Title: MK3475-651-00 A phase 1b multi-cohort study of the combination of pembrolizumab (MK-3475) plus binimetinib alone or the combination of pembrolizumab plus chemotherapy with or without binimetinib in participants with metastatic colorectal cancer (KEYNOTE-651)  
 Total costs: \$572,284  
 Role: Local PI
- 2018-2022 Sponsor: AADi  
 Title: ABI-009 COLO A phase 1/2 multi-center investigation of ABI-009 (nab-rapamycin) in combination with FOLFOX and bevacizumab as first-line therapy in patients with advanced or metastatic colorectal cancer  
 Total costs: \$750,152

- 2019-2023 Role: Local PI  
Sponsor: Rafael Pharmaceuticals, Inc.  
Title: PANC003 Phase 3 multicenter open-label randomized trial to evaluate efficacy and safety of FOLFIRINOX (FFX) versus combination of CPI-613 with modified FOLFIRINOX (mFFX) in patients with metastatic adenocarcinoma of the pancreas.  
Total costs: \$142,201
- 2019-2024 Role: Local PI  
Sponsor: Fibrogen  
Title: FGCL-3019-087 Phase 3, randomized, double-blind study of pamrevlumab or placebo in combination with gemcitabine/nab-paclitaxel or FOLFIRINOX in patients with locally advanced, unresectable pancreatic adenocarcinoma.  
Total costs: \$666,054
- 2019-2024 Role: Local PI  
Sponsor: Pancreatic Cancer Action Network (PanCan)  
Title: Precision Promise clinical trial in pancreatic cancer  
Total costs: \$120,000
- 2020-2023 Role: Local Co-PI (PI-Coveler)  
Role: National PI, control arm Gemcitabine/*nab*-paclitaxel  
Sponsor: Corcept Therapeutics  
Title: CORT125134-553 A Phase 2 Study of Relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (RELIANT)  
Total costs: \$560,678
- 2021-2023 Role: Local PI  
Sponsor: BioMed Valley  
Title: BVD-523-ABC A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations  
Total costs: \$671,296
- 2022 Role: Local PI  
Sponsor: BioSplice  
Title: SM08502-ONC-03 A Phase 1b, open-label, dose-escalation, dose-expansion study evaluating the safety, pharmacokinetics, and efficacy of orally administered SM08502 combined with hormonal therapy or chemotherapy in subjects with advanced solid tumors  
Total Costs: \$758,126.00
- 2023-2024 Role: Local PI  
Sponsor: Gilead  
Title: A phase 2, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with bevacizumab and FOLFIRI versus bevacizumab and FOLFIRI in previously treated advanced inoperable metastatic colorectal cancer  
Total Costs: \$998,064  
Role: Local PI

## 16. BIBLIOGRAPHY

### A. Publications in Refereed Journals

1. **Chiorean EG**, Miller JS. The biology of natural killer cells and implications for therapy of human disease. *J Hematother Stem Cell Res* 2001; 10:451-463 [review]

2. **Chiorean EG**, Dylla SJ, Olsen K, Lenvik T, Soignier YM, Miller JS. BCR/ABL alters the function of NK cells and the acquisition of Killer Immunoglobulin-like receptors (KIR). *Blood* 2003; 101:3527-3533 [original work]
3. Repka T, **Chiorean EG**, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS. Trastuzumab and IL-2 in HER-2 positive metastatic breast cancer: a pilot study. *Clin Cancer Res* 2003;9: 2440-2446 [original work]
4. **Chiorean EG**, DeFor TE, Weisdorf DJ, Blazar BR, McGlave PB, Burns LJ, Brown C, Miller JS. Donor chimerism does not predict response to DLI for relapsed CML after allogeneic stem cell transplantation. *Biol Blood Marrow Transplant* 2004; 10:171-177 [original work]
5. Cardenes H, **Chiorean EG**, DeWitt J, Schmidt M, Loehrer PJ. Locally advanced pancreatic cancer: current therapeutic approach. *Oncologist* 2006;11:612-623 [review]
6. **Chiorean EG**, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, Colowick AB, Tidmarsh GF, Loehrer PJ. A phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. *Cancer Chemother Pharmacol* 2008;61:1019-1026 [original work]
7. **Chiorean EG**, Porter J, Foster AE, Al Omari ASH, Yoder CA, Fife KL, Yu M, Strother RM, Murry DJ, Jones DR, Sweeney CJ. A phase I and pharmacokinetic trial of erlotinib in combination with weekly docetaxel in patients with taxane naïve malignancies. *Clinical Cancer Research* 2008; 14:1131-1137 [original work]
8. Struck A, Howard T, **Chiorean EG**, Clarke JM, Riffenburgh R, Cardenes H. Non-ampullary duodenal adenocarcinoma: factors important for relapse and survival. *J Surg Oncol* 2009; 100:144-148 [original work]
9. **Chiorean EG**, Dragovich T, Hamm J, Barrios CH, Gorini CFN, Langmuir VK, Kroll S, Jung DT, Tidmarsh GT, Loehrer PJ. A Phase 2 trial of Glufosfamide in combination with Gemcitabine in chemotherapy-naïve pancreatic adenocarcinoma. *Am J Clin Oncol* 2010; 33:111-116 [original work]
10. **Chiorean EG**, Malireddy S, Younger AE, Jones DR, Waddell MJ, Margol M, Yu M, Hall SD, Schneider B, Sweeney CJ. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2010; 66:441-448 [original work]
11. Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, **Chiorean EG**, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I, pharmacologic and biologic study of Ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the Vascular Endothelial Growth Factor Receptor-2. *J Clin Oncol* 2010; 28:780-787 [original work]
12. Akisik F, Sandrasegaran K, Bu G, Lin C, Hutchins GD, **Chiorean EG**. Pancreatic cancer: Utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. *Radiology* 2010; 256:441-449 [original work]
13. Sweeney C, **Chiorean EG**, Verschraegen CF, Lee FC, Jones S, Royce M, Tye L, Liau KF, Bello A, Chao R, Burris HA. A Phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. *J Clin Oncol* 2010; 28:4513-4520 [original work]
14. Heath EI, **Chiorean EG**, Sweeney CJ, Hodge JP, Lager JJ, Forman K, Malburg L, Arumugham T, Dar MM, Suttle AB, Gainer SD, LoRusso P. A phase I study of the pharmacokinetic and safety profile of oral pazopanib dosing with a high-fat or low-fat meal in patients with advanced solid tumors. *Clin Pharmacol Ther* 2010; 88:818-823 [original work]
15. Cardenes H, Moore AM, Johnson CS, Yu M, Helft P, **Chiorean EG**, Vinson J, Howard T, Stephens AW, Tai DF, Loehrer PJ. A phase II study of Gemcitabine in combination with radiation therapy in patients with localized, unresectable pancreatic cancer: a Hoosier Oncology Group study. *Am J Clin Oncol* 2011; 34:460-465 [original work]

16. Tolcher A, Sweeney CJ, Papadopoulos K, Patnaik A, **Chiorean EG**, Mita AC, Sankhala K, Furfine E, Gokemeijer J, Iacono L, Eaton C, Silver BA, Mita M. Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin. *Clin Cancer Res* 2011; 17:363-371 [original work]
17. Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q, Schmidt CM, **Chiorean EG**, Xie J, Cheng L, Chen JH, Zhang JT. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. *Int J Biochem Mol Biol* 2011; 2:89-98 [original work]
18. Weiss GJ, Infante JR, **Chiorean EG**, Borad M, Bendell J, Molina J, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, Kroll S, Langmuir VK, Lee H, Burris H. Phase I study of the safety, tolerability and pharmacokinetics of TH-302, a hypoxia-activated prodrug in patients with advanced solid malignancies. *Clin Cancer Res* 2011; 17:2997-3004 [original work]
19. \*Beatty GL, **Chiorean EG**, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. CD40 activation regulates cancer inflammation and induces regression of pancreatic carcinoma in mice and humans. *Science* 2011;331: 1612-1616 [original work]
20. Abou-Alfa GK, Chan SL, Lin CC, **Chiorean EG**, Holcombe RF, Mulcahy MF, Carter WD, Wilson WR, Melink TR, Gutheil JC, Tsao CJ. PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma. *Cancer Chemother Pharmacol* 2011;68: 539-545 [original work]
21. Galsky MD, Camacho LH, **Chiorean EG**, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Phase I study of the effects of renal impairment on the pharmacokinetics and safety of satraplatin in patients with refractory solid tumors. *Ann Oncol* 2012; 23:1037-1044 [original work]
22. Galsky MD, Seng S, Camacho LH, **Chiorean EG**, Mulkerin D, Hong DS, Oh WK, Bajorin DF. Retrospective analysis of Satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. *Clin Genitourin Cancer* 2011; 9:27-30 [original work]
23. Davis T, Summerlin DJ, Moore M, Younger A, **Chiorean EG**. Mandibular fracture in a patient treated with long-term anti-angiogenic therapy and prior biphosphonate exposure. *Community Oncology* 2011; 8:415-417 (corresponding author) [case report]
24. **Chiorean EG**, Ramasubhaiah R, Yu M, Picus J, Bufill JA, Tong Y, Johnston EL, Currie C, Loehrer PJ. Multicenter phase II trial of erlotinib with docetaxel in advanced hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. *Oncologist* 2012; 17:13 [original work]
25. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; **RADIANT-2 Study Group (Chiorean E)**. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): a randomized, placebo-controlled, phase 3 study. *Lancet* 2011; 378: 2005-2012 [original work]
26. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, **Chiorean EG**, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith W. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. *Clin Cancer Res* 2012; 18: 1092-1100 [original work]
27. **Chiorean EG**, Sanghani S, Schiel MA, Yu M, Burns M, Tong Y, Hinkle DT, Coleman N, Robb B, LeBlanc J, Clark R, Bufill J, Curie C, Loehrer PJ, Cardenes H. Phase II and gene expression analysis trial of preoperative capecitabine plus irinotecan followed by capecitabine-based radiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. *Cancer Chemother Pharmacol* 2012; 70:25-32 [original work]
28. Mahadevan D, **Chiorean EG**, Harris WB, Von Hoff DD, Stejskal-Barnett A, Qi W, Anthony SP, Younger AE, Rensvold DM, Cordova F, Shelton CF, Becker MD, Garlich JR, Durden

- DL, Ramanathan RK. Phase I pharmacokinetic and pharmacodynamics study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumors and B-cell malignancies *Eur J Cancer* 2012; 48:3319-3327 [original work]
29. Hardacre JM, Mulcahy M, Small W, Talamonti M, Obel J, Krishnamurthi S, Rocha-Lima CS, Safran H, Lenz HJ, **Chiorean EG**. Addition of Algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. *J Gastrointest Surg* 2013; 17:94-100 [original work]
30. Raez LE, Papadopoulos K, Ricart AD, **Chiorean EG**, DiPaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis T. A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2013; 71:523-530 [original work]
31. Song B, Liu XS, Rice S, Kuang S, Elzey BD, Konieczny SF, Ratliff T, Hazbun T, **Chiorean EG**, Liu X. Plk1 phosphorylation of Orc2 and Hbo1 contributes to gemcitabine resistance in pancreatic cancer. *Molec Cancer Ther* 2013; 12:58-68 [original work]
32. Chen N, Chawla SP, **Chiorean EG**, Read WL, Gorbaty M, Mita AC, Yung L, Bryan P, McNally R, Renschler MF, Sharma S. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization through QT/QTc measurements of amrubicin and its active metabolite amrubicinol in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2013; 71:1083-1094 [original work]
33. Cai H, **Chiorean EG**, Chiorean M, Rex DK, Robb B, Hahn N, Liu Z, Xu Y. Elevated phospholipase A2 activities in plasma samples from multiple cancers. *PLoS One* 2013;8: e57081 [original work]
34. Gu D, Liu H, Zhang X, Chin-Sinex H, Hanenberg H, Mendonca M, Shannon HE, **Chiorean EG**, Xie J. Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. *Molec Cancer Ther* 2013;12: 1038-1048 [original work]
35. \*Von Hoff DD, Ervin T, Arena FP, **Chiorean EG**, Infante J, Moore M, Seay T, Tjulandin SA, Ma W, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. *New Engl J Med* 2013; 369:1691-1703 [original work]
36. Beatty GL, Torigian DA, **Chiorean EG**, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, O'Dwyer PJ. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2013; 19:6286-6295 [original work]
37. **Chiorean EG**, Von Hoff DD. Taxanes: Impact on Pancreatic Cancer. *Anticancer Drugs* 2014; 25:584-592 [review]
38. **Chiorean EG**, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFR $\alpha$ ) monoclonal antibody, in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2014; 73:595-604 [original work]
39. Hocevar BA, Kamendulis LM, Pu X, Perkins SM, Wang ZY, Johnston EL, DeWitt JM, Li L, Loehrer PJ, Klauinig JE, **Chiorean EG**. Contribution of environment and genetics to pancreatic cancer susceptibility. *PLoS One* 2014; 9(3): e90052 [original work]
40. **Chiorean EG**, Schneider BP, Akisik FM, Perkins SM, Anderson S, Johnson CS, DeWitt J, Helft P, Clark R, Johnston EL, Spittler AJ, Deluca J, Bu G, Shahda S, Loehrer PJ, Sandrasegaran K, Cardenas HR. Phase I, pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiotherapy and gemcitabine in locally advanced unresectable pancreatic cancer. *Int J Rad Oncol Biol Phys* 2014; 89:284-291 [original work]

41. LoRusso P, Venkatakrisnan K, **Chiorean EG**, Noe D, Wu JT, Sankoh S, Corvez M, Sausville E. Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of Epidermal Growth Factor Receptor and Human Epidermal Growth Factor Receptor 2 (HER2). *Invest New Drugs* 2014; 32:160-170 [original work]
42. Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, **Chiorean EG**, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA. Pancreatic adenocarcinoma, version 2.2014. *J Natl Compr Canc Netw* 2014;12:1083-1093 [review/curriculum development]
43. Khawaja MR, Kleyman S, Yu Z, Howard T, Burns M, Nakeeb A, Loehrer PJ, Cardenes HR, **Chiorean EG**. Adjuvant gemcitabine and gemcitabine-based chemoradiotherapy versus gemcitabine alone after pancreatic cancer resection: the Indiana University experience. *Am J Clin Oncol* 2014 Aug 13; PMID 25121637 [original work]
44. Zhu J, Djukovic D, Deng L, Gu H, Himmati F, **Chiorean EG**, Raftery D. Colorectal cancer detection using targeted serum metabolic profiling. *J Proteome Res* 2014;13: 4120-4130 [original work]
45. Gordon MS, Robert F, Rosen LS, Matei D, Mendelson DS, Goldman JW, **Chiorean EG**, Strother RM, Seon BK, Figg WD, Peer CJ, Alvarez D, Adams BJ, Theuer CP. An open label phase Ib dose escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. *Clin Cancer Res* 2014; 20:5918-5926 [original work]
46. Tabernero J, **Chiorean EG**, Infante JR, et al. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. *Oncologist* 2015; 20:143-150 [original work]
47. Borad MJ, Reddy SG, Bahary N, Uronis HE, Sigal D, Cohn AL, Schelman WR, Stephenson J Jr, **Chiorean EG**, Rosen PJ, Ulrich B, Dragovich T, Del Prete SA, Rarick M, Eng C, Kroll S, Ryan DP. Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic cancer. *J Clin Oncol* 2015; 33:1475-1481 [original work]
48. Owusu-Sarfo K, Asiago VM, Deng L, Gu H, Wei S, Shanaiah N, Gowda GAN, Xi B, **Chiorean EG**, Raftery D. NMR-based metabolite profiling of pancreatic cancer. *Curr Metabol* 2014; 2:204–212 [original work]
49. Khawaja MR, Minturn JT, Spittler AJ, **Chiorean EG**. Ocular metastasis of colorectal cancer: an uncommon presentation of a common malignancy. *Hematol Oncol Stem Cell Ther* 2015; 8:176-180 [case report]
50. **Chiorean EG**, LoRusso P, Strother RM, Diamond JR, Younger A, Messersmith WA, Adriaens L, Liu L, Kao RJ, DiCioccio AT, Kostic A, Leek R, Harris A, Jimeno A. A phase I first-in-human study of enoticumab (REGN421), a fully human Delta-like ligand 4 (Dl4) monoclonal antibody in patients with advanced solid tumors. *Clin Cancer Res* 2015; 21: 2695-2703 [original work]
51. Tabernero J, Chawla S, Kindler H, Reckamp K, **Chiorean EG**, Azad NS, Lockhart AC, Hsu CP, Baker NF, Galimi F, Beltran P, Baselga J. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. *Target Oncol* 2015; 10:65-76 [original work]
52. \***Chiorean EG**, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ. Phase I study of every 2- or 3- week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. *Ann Oncol* 2015; 26:1230-1237 [original work]

53. Gu H, Du J, Carnevale Neto F, Caroll P, Turner S, **Chiorean G**, Eisenman R, Raftery D. Metabolomics method to comprehensively analyze amino acids in different domains. *Analyst* 2015; 140:2726-2734 [original work]
54. Chen C, Deng L, Wei S, Gowda GAN, Gu H, **Chiorean G**, Zaid M, Harrison M, Pekny J, Loehrer P, Zhang D, Zhang M, Raftery D. Exploring metabolic profile differences between colorectal polyp patients and controls using seemingly unrelated regression. *J Proteome Res* 2015; 14:2492-2499 [original work]
55. **Chiorean EG**, Coveler AL. Pancreatic cancer: optimizing treatment options, new, and emerging targeted therapies. *Drug Des Devel Ther* 2015; 9:3529-3545 [review]
56. Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Abu Zaid M, **Chiorean EG**, Raftery D. Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring. *Anal Bioanal Chem* 2015; 407:7857-7863 [original work]
57. McCormick KA, Coveler AL, Rossi GR, Vahanian N, Link C, **Chiorean EG**. Pancreatic cancer: update on immunotherapies and Algenpantucel-L. *Hum Vaccin Immunother* 2016; 12(3):563-575 [review]
58. Coveler AL, Rossi GR, Vahanian NN, Link C, **Chiorean EG**. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma. *Immunotherapy* 2016;8(2):117-125 [review]
59. **Chiorean EG**, Von Hoff DD, Ervin TJ, Arena FP, Infante JR, et al. CA19-9 decrease at 8 weeks as predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. *Ann Oncol* 2016;27(4): 654-660 [original work]
60. Coveler AL, Richard PJ, Apisarnthanarax, **Chiorean EG**. Is there a best radiosensitizing agent in the treatment of locally advanced rectal cancer? *Current Colorectal Cancer Reports* 2016; 12(4):189-200 [review]
61. Shahda S, Loehrer PJ, Clark RS, Spittler AJ, Althouse SK, **Chiorean EG**. Phase I study of lenalidomide and sorafenib in patients with advanced hepatocellular carcinoma. *Oncologist* 2016; 21(6):664-665 [original work]
62. Coveler AL, Herman JM, Simeone DM, **Chiorean EG** (corresponding author). Localized pancreatic cancer: multidisciplinary management. *Am Soc Clin Oncol Educ Book* 2016; 35: e217-26 [review].
63. **Chiorean EG**, Von Hoff DD, Tabernero J, El-Maraghi R, Wee Ma W, Reni M, Harris M, Whorf R, Liu H, Shiansong Li J, Manax V, Romano A, Lu B, Goldstein D. Second-line therapy after nab-paclitaxel plus gemcitabine or gemcitabine for patients with metastatic pancreatic cancer: a subanalysis of the MPACT trial. *Br J Cancer* 2016; 115:188-194. [original work]
64. Ramanathan RK, Korn RL, **Chiorean EG**, Liu H, Von Hoff DD. Positron emission tomography (PET) as predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline. *Ann Oncol* 2016; 27(8): 1647-1648 [original work]
65. Saif MW, Knost JA, **Chiorean EG**, Kambhampati SR, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH. Phase I study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer. *Cancer Chemother Pharmacol* 2016; 78(4):815-824 [original work]
66. Deng L, Gu H, Nagana Gowda GA, Djukovic D, **Chiorean EG**, Raftery D. Combining NMR and LC/MS using backward variable elimination: metabolomics analysis of colorectal cancer, polyps, and healthy controls. *Anal Chem* 2016; 88(16): 7975-7983. [original work]
67. LoRusso PM, Gounder M, Jalal SI, Andre V, Prasad Kambhampati SR, Loizos N, Hall J, Holzer TR, Nasir A, Cosaert J, Kauh J, **Chiorean EG**. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. *Invest New Drugs* 2017; 35(4): 442-450. [original work]

68. Burstein H, Krilov L, Aragon-Ching J, Baxter N, **Chiorean EG**, Chow WA, de Groot JF, Devine SM, DuBois S, El-Deiry WS, Epstein AS, Heymach JV, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung NM, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual report on progress against cancer from the American Society of Clinical Oncology. *J Clin Oncol* 2017; 35(12): 1341-1367 [original work].
69. Kim R, **Chiorean EG**, Amin M, Rocha-Lima CM, Gandhi J, Harris W, Portnoy D. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. *Br J Cancer* 2017; 117(2):189-194. [original work]
70. Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, **Chiorean EG**, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2017; 15(8): 1028-1061. [review/curriculum development]
71. Chen C, Nagana Gowda GA, Zhu J, Deng L, Gu H, **Chiorean EG**, Abu Zaid M, Harrison M, Zhang D, Zhang M, Raftery D. Altered metabolite levels and correlations in patients with colorectal cancer and polyps detected using seemingly unrelated regression analysis. *Metabolomics* 2017; 13:125 [original work]
72. Meropol NJ, Feng Y, Grem JL, Mulcahy MF, Kauh JS, Hall MJ, Saltzman JN, George TJ, Zangmeister J, **Chiorean EG**, Cheema PS, O'Dwyer PJ, Benson AB. Phase II study of treatment selection based upon tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: a trial of the ECOG-ACRIN Cancer Research Group (E4203). *Cancer* 2018; 124(4): 688-697 [original work]
73. Chan E, **Chiorean EG**, Gabrail NY, Alcindor T, Potvin D, Chao R, Hurwitz H. Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors. *Cancer Chemother Pharmacol* 2018; 81(2):355-364 [original work]
74. Chittiboyina S, Chen Z, **Chiorean EG**, Kamendulis LM, Hocevar BA. The role of folate pathway in pancreatic cancer risk. *PLoS One* 2018 Feb 23;13(2) e0193298 [original work]
75. **Chiorean EG**, Von Hoff D, Wan Y, Margunato-Debay S, Botteman M, Goldstein D. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. *Cancer Manag Res* 2018; 10: 1389-1396. [original work]
76. Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, **Chiorean EG**, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grenman RA, Caporiccio L, McKee TD, Zaidi M, Butt S, Macann AM, Mclvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. *JCI Insight* 2018;3(16). doi: 10.1172/jci.insight. 122204 [original work]
77. Zhen DB, Coveler A, Zanon S, Reni M, **Chiorean EG**. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma. *Semin Oncol* 2018; 45(3):107-115 [review]
78. Gbolahan OB, Porter RF, Salter JT, Yiannoutsos C, Burns M, **Chiorean EG**, Loehrer PJ Sr. A phase II study of pemetrexed in patients with recurrent thymoma and thymic carcinoma. *J Thorac Oncol* 2018; 13(12):1940-1948 [original work]

79. Jia Y, Gu D, Wan J, Yu B, Zhang X, **Chiorean EG**, Wang Y, Xie J. The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer. *Oncogene* 2019; 38(10): 1764-1777 [original work]
80. Hendifar AE, Petzel MQB, Zimmers TA, Denlinger CS, Matrisian LM, Picozzi VJ, Rahib L, **Chiorean EG** Precision Promise Consortium. Pancreas Cancer-Associated weight loss. *Oncologist* 2019; 24(5): 691-701 [review]
81. Ramanathan RK, McDonough SL, Philip PA, Hingorani SR, Lacy J, Kortmansky JS, Thumar J, **Chiorean EG**, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS. Phase IB/II randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus FOLFIRINOX alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313. *J Clin Oncol* 2019; 37(13): 1062-1069 [original work]
82. Tempero MA, Malafa MP, **Chiorean EG**, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WH, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G. Pancreatic adenocarcinoma, Version 1.2019. *J Natl Compr Canc Netw*. 2019; 17(3): 202-210. [NCCN guidelines; review]
83. Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, **Chiorean EG**, Sloan J, Lacouture ME, Lenz HJ, Grothey A. Regorafenib dose optimization in patients with refractory metastatic colorectal cancer (ReDOS): a randomized, multicentre, open label, phase 2 study. *Lancet Oncol*. 2019; 20(8): 1070-1082 [original work]
84. **Chiorean EG**, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in advanced pancreatic cancer: a systematic review. *Ther Adv Med Oncol* 2019 May 29; 11:1758835919850367 [review]
85. Karasic T, **Chiorean EG**, Sebti S, O'Dwyer P. A phase I study of GGTI-2418 (geranylgeranyl transferase I inhibitor) in patients with advanced solid tumors. *Target Oncol*. 2019; 14(5): 613-618. [original work]
86. **\*Chiorean EG**, Nandakumar G, Fadelu T, Temin S, Alarcon-Rozas AE, Bejarano S, Croitoru AE, Grover S, Lohar PV, Ohiambo A, Park SH, Ruiz Garcia E, Rose A, Zaki B, Chamberlin MD. Treatment of patients with late-stage colorectal cancer: ASCO resource-stratified guideline. *JCO Glob Oncol* 2020; 6:414-438 [guidelines]
87. Bullock A, Rowan CG, Oestreicher N, Yeganegi H, **Chiorean EG**. Real-world assessment of health care costs for patients with metastatic pancreatic cancer following initiation of first-line chemotherapy. *J Manag Care Spec Pharm* 2020; 26(7):872-878 [original work]
88. Goldstein D, Von Hoff DD, **Chiorean EG**, Reni M, Tabernero J, Ramanathan RK, Botteman M, Aly A, Margunato-Debay S, Lu B, Louis C, Renschler M, McGovern D, Lee C. Nomogram for estimating overall survival in patients with metastatic pancreatic cancer. *Pancreas* 2020; 49(6):744-750 [original work]
89. Wainberg ZA, Hochster HS, Kim EJ, George B, Kaylan A, **Chiorean EG**, Waterhouse DM, Guitierrez M, Parikh A, Jain R, Carrizosa DR, Soliman HH, Lila T, Reiss DJ, Pierce D, Bhore R, Banerjee S, Lyons L, Louis CU, Ong TJ, O'Dwyer PJ. Open-label, phase 1 study of nivolumab combined with nab-paclitaxel plus gemcitabine in advanced pancreatic cancer. *Clin Cancer Res* 2020; 26(18): 4814-4822 [original work]
90. Ahmad SA, Duong M, Sohal DPS, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3<sup>rd</sup>, **Chiorean EG**, Guthrie KA, Lowy AM, Hochster HS. Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX vs gemcitabine/nab-paclitaxel for perioperative treatment of resectable pancreatic ductal adenocarcinoma. *Ann Surg Oncol* 2020;272(3):481-486. [original work]

91. **Chiorean EG**, Perkins S, Strother RM, Younger A, Funke JM, Shahda SG, Hahn NM, Sandrasegaran K, Jones DR, Skaar TC, Schneider BP, Sweeney C, Matei DE. Phase I, pharmacogenomic, drug-interaction study of sorafenib and bevacizumab in combination with paclitaxel in patients with advanced solid tumors. *Molec Cancer Ther* 2020; 19(10):2155-2162 [original work]
92. Sohal DPS, Duong M, Ahmad SA, Gandhi NS, Beg MS, Wang-Gillam A, Wade JL 3rd, **Chiorean EG**, Guthrie KA, Lowy AM, Philip PA, Hochster HS. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. *JAMA Oncol.* 2021; 7(3):421-427 [original work]
93. Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen K, Barzi A, **Chiorean EG**, Heying EN, Lenz HJ, Sloan J, Grothey A, Lacouture M, Bekaii-Saab T. Pre-emptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: a pre-planned analysis of the ReDOS trial. *Oncologist.* 2021; 26(7): 610-618 [original work]
94. Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, **Chiorean EG**, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Dotan E, Ferrone CR, Fountzilas C, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Moravek C, Nakakura EK, Narang AK, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Vollmer C, Wolff RA, Wolpin BM, Lynn B, George GV. Pancreatic adenocarcinoma, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw.* 2021;19(4):439-457 [guidelines]
95. Chang AE, Radke M, Zhen DB, Baker KK, Coveler AL, Wong KM, Pillarisetty VG, Redman M, Swisher E, **Chiorean EG**. DNA repair defects by BROCA-HR and survival outcomes for patients with resected pancreatic ductal adenocarcinomas. *Pancreas* 2021 May-Jun 01; 50(5): e50-e52. [original work]
96. Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, **Chiorean EG**, O'Hara MH, Liudahl SM, Newcomb CW, Alanio C, Ferreira AP, Park BS, Ohtani T, Huffman AP, Väyrynen SA, Dias Costa A, Kaiser JC, Lacroix AM, Redlinger C, Stern M, Nowak JA, Wherry EJ, Cheever MA, Wolpin BM, Furth EE, Jaffee EM, Coussens LM, Vonderheide RH. Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer. *Clin Cancer Res* 2021; 27(16):4574-4586. [original work]
97. **\*Chiorean EG**, Guthrie K, Philip PA, Swisher EM, Jalikis F, Pishvaian MJ, Berlin J, Noel MS, Suga JM, Garrido-Laguna I, Cardin DB, Radke MR, Duong M, Bellasea S, Lowy AM, Hochster HS. Randomized Phase II Study of PARP inhibitor ABT-888 (Veliparib) with modified FOLFIRI versus FOLFIRI as second line treatment of metastatic pancreatic cancer: SWOG S1513. *Clin Cancer Res* 2021; 27(23): 6314-6322. [original work]
98. King G, Green S, **Chiorean EG**. Finding a role for cancer vaccines in pancreatic cancer: a model of resilience. *Hepatobiliary Surg Nutr* 2022;11(1):115-118. [editorial]
99. Diehl AC, Hannan LM, Zhen DB, Coveler AL, King G, Cohen SA, Harris WP, Shankaran V, Wong KM, Green S, Ng N, Pillarisetty VG, Sham J, Park JO, Reddi D, Konnick EQ, Pritchard CC, Baker K, Redman M, **Chiorean EG**. KRAS mutation variants and co-occurring PI3K pathway alterations impact survival for patients with pancreatic adenocarcinomas. *The Oncologist* 2022; 27(12): 1025-1033. [original work]
100. Gösling GCL, Zhen DB, Pillarisetty VG, **Chiorean EG**. Combination immunotherapy for pancreatic cancer: challenges and future considerations. *Expert Rev Clin Immunol* 2022; 18(11):1173-1186. [review]
101. Jamieson SM, Tsai P, Kondratyev MK, Budhani P, Liu A, Senzer NN, **Chiorean EG**, Jalal SI, Nemunaitis JJ, Kee D, Shome A, Wong WW, Li D, Poonawala-Lohani N, Kakadia PM, Knowlton NS, Lynch CR, Hong CR, Lee TW, Grénman RA, Caporiccio L, McKee TD, Zaidi

- M, Butt S, Macann AM, Mclvor NP, Chaplin JM, Hicks KO, Bohlander SK, Wouters BG, Hart CP, Print CG, Wilson WR, Curran MA, Hunter FW. Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma. *JCI Insight*. 2023;8(4): e169136. [erratum]
102. Zhen DB, Safyan RA, Konnick EQ, Nguyen R, Pritchard C, **Chiorean EG**. The role of molecular testing in pancreatic cancer. *Ther Adv Gastroenterol* 2023 May 12; 16: 17562848231171456. doi: 10.1177/17562848231171456. [review]
103. Luke JJ, Fakih M, Schneider C, **Chiorean EG**, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O'Hayer K, Geschwindt R, Smith M, Zhou F, Naing A. Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. *Br J Cancer*. 2023; 28(12):2227-2235 [original work]
104. Cohen SA, Veleber S, Siman J, Guthrie KL, McMillen K, Heit M, Wadhera S, Daniels J, Hansen K, Jacoby M, Taromina K, Chin S, Romeo M, Langley BO, Coveler AL, Hannan LM, King G, Purcell T, Safyan RA, Shankaran V, Zhen DB, **Chiorean EG**, Greenlee H. Use of acupuncture with acupressure in addition to standard-of-care cryotherapy to decrease chemotherapy-associated neuropathy in patients with gastrointestinal malignancies receiving oxaliplatin-based chemotherapy: Study protocol for a randomized, controlled pilot and feasibility study. *Contemp Clin Trials*. 2023 Jun 26; 131: 107273. [original work]
105. Tempero MA, Pelzer U, O'Reilly EM, et al; **Chiorean E** among APACT Investigators. Adjuvant *nab*-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. *J Clin Oncol*. 2023;41(11):2007-2019. [original research]
106. **Chiorean EG**, Chiaro MD, Tempero MA, Malafa MP, Benson AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilas C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Reddy S, Reyngold M, Scaife C, Shen J, Truty MJ, Vollmer C, Wolff RA, Wolpin BM, Rn BM, Lubin S, Darlow SD. Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw*. 2023;21(7):753-782. [guidelines]
107. Coveler A, Pillarisetty VG, Zhen DB, Park JO, King GG, Sham J, Mann G, Hannan LM, Baker K, Redman M, Swanson PE, Upton MP, **Chiorean EG**, Whiting S. Perioperative chemotherapy and chemoradiotherapy for patients with resectable and borderline resectable pancreatic adenocarcinoma. *Pancreas* 2023 52(5): e282-e287. [original research]
108. **Chiorean EG**, Picozzi V, Li CP, Peeters M, Maurel J, Singh J, Golan T, Blanc JF, Chapman SC, Hussain AM, Johnston EL, Hochster HS. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial. *Cancer Med* 2023;12(20):20353-20364 [original research]
109. Wattenberg MM, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Beg MS, Wang-Gillam A, Wade III JL, Guthrie KA, **Chiorean EG**, Ahmad SA, Lowy AM, Philip PA, Sohal DPS, Beatty GL. Intra-tumoral cell neighborhoods drive outcomes in pancreatic ductal adenocarcinoma. *Gastroenterology* 2024;166(6):1114-1129. [original research].
110. Sohal DPS, Boutin RD, Lenchik L, Kim J, Beg MS, Wang-Gillam A, Wade JL 3rd, Guthrie KA, **Chiorean EG**, Ahmad SA, Lowy AM, Philip PA, Chang VT. Body composition measurements and clinical outcomes in patients with resectable pancreatic adenocarcinoma - analysis from SWOG S1505. *J Gastrointest Surg*. 2024;28(3):232-235.
111. Cloyd JM, Colby S, Guthrie KA, Lowy AM, **Chiorean EG**, Philip P, Sohal D, Ahmad S. Failure to undergo resection following neoadjuvant therapy for resectable pancreatic cancer: a secondary analysis of SWOG S1505. *J Natl Compr Canc Netw* 2024; 29:1-6. [original research].

112. Kim R, Tehfe M, Kavan P, Chaves J, Kortmansky JS, Chen EX, Lieu CH, Wong L, Fakih M, Spencer K, Zhao Q, Predoiu R, Li C, Leconte P, Adelberg D, **Chiorean EG**. Pembrolizumab plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient metastatic colorectal cancer: outcomes from KEYNOTE-651 cohorts B and D. *Clin Colorectal Cancer* 2024; 23(2):118-127. [original research]
113. Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MB, **Chiorean EG**, Lieu CH, Polite B, Wong L, Fakih M, Spencer K, Chaves J, Li C, Leconte P, Adelberg D, Kim R. Pembrolizumab plus binimetinib with or without chemotherapy for MSS/pMMR metastatic colorectal cancer: outcomes from KEYNOTE-651 Cohorts A, C, and E. *Clin Colorectal Cancer*. 2024; 23(2):183-193. [original research]
114. Safyan RA, Kim E, Dekker E, Homs M, Aguirre AJ, Groot Koerkamp B, **Chiorean EG**. Multidisciplinary standards and evolving therapies for patients with pancreatic cancer. *Am Soc Clin Oncol Educ Book*. 2024;44(3): e438598. [review]
115. Borazanci EH, Bahary N, Chung V, Huyck TK, Kio EA, **Chiorean EG**, Skeel RT, Alese OB, Cardin DB, Fountzilias C, Hanna WT, Leal AD, Lee V, Noonan AM, Philip PA, Wainberg ZA, Pashova H, Mann G, Oberstein PE. Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. *Oncologist*. 2024 Aug 26; doi:10.1093/oncolo/oyae210. PMID: 39191530. [original research]
116. **Chiorean EG**. Is it Time to Forget the 5-Fluorouracil Bolus? *J Natl Compr Canc Netw*. 2024 Oct;22(8):577-579. [editorial]
117. Yamamoto N, Dobersch S, Loveless I, Samraj A, Jang GH, Haraguchi M, Kang LI, Ruzinova M, Vij K, Mudd J, Walsh T, Safyan R, **Chiorean EG**, Li L, Fields R, DeNardo D, Notta F, Crawford H, Steele N, Kugel S. HMGA2 expression predicts subtype, survival, and treatment outcome in pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2025;31(4):733-745. [original research]
118. Shroff RT, King G, Colby S, Scott AJ, Borad MJ, Goff L, Matin K, Mahipal A, Kalyan A, Javle MM, El Dika I, Tan B, Cheema P, Patel A, Iyer R, Kelley R, Thumar J, El-Khoueiry A, Guthrie KA, **Chiorean EG**, Hochster H, Philip PA: SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. *J Clin Oncol*. 2025;43(5):536-544. [original research]
119. Raghav K, Guthrie KA, Tan B, Denlinger CS, Fakih M, Overman MJ, Dasari NA, Corum LR, Hicks LG, Patel MS, Esparaz BT, Kazmi SM, Alluri N, Colby S, Gholami S, Gold PJ, **Chiorean EG**, Kopetz S, Hochster HS, Philip PA. Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patient with *RAS/BRAF* wild-type, HER2-positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase 2 Trial. *J Clin Oncol* 2025 Jan 6: JCO2401710. doi: 10.1200/JCO-24-01710. PMID: 39761503. [original research]
120. Patel SH, Colby S, Sohal D, Guthrie KA, Kachnic LA, **Chiorean EG**, Lowy AM, Rocha FG, Hochster HS, Philip PA, Ahmad SA. Chemotherapy dose-density is prognostic for overall survival in patients with resectable pancreas cancer: a landmark analysis of SWOG 1505. *Cancer* 2025;131(4): e35759. doi: 10.1002/cncr.35759. PMID: 39932777. [original research]
121. Saeed A, Colby S, Oberstein PE, Duda DG, Park R, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger JM, Guthrie KA, Rocha FG, Senthil M, Safyan RA, Wainberg ZA, Iqbal S, **Chiorean EG**, Philip PA. S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). *Future Oncol*. 2025 Mar 28:1-7. doi: 10.1080/14796694.2025.2485020
122. Safyan RA, Zhang K, Apisarnthanarax S, Sham J, Pillarisetty V, Kugel S, Dubard-Gault M, Pritchard CC, Konnick EQ, Sahani D, **Chiorean EG**. Long-term survival following chemoradiation in locoregional recurrent germline ATM mutated pancreatic ductal adenocarcinoma. *Adv Radiat Oncol*. 2025 Feb 21;10(4):101742. doi: 10.1016/j.adro.2025.101742. PMID: 40161544 [case report]

123. Damle S, Pillarisetty V, Safyan R, **Chiorean EG**. A New Dawn in Cancer Immunotherapy: The Promise of Mutant KRAS-Specific Vaccines. *Transl Gastroenterol Hepatol* 2025 [editorial; in press]

#### B. Book Chapters

1. **Chiorean EG**: Gastrointestinal Cancers Chapter, Yearbook in Oncology 2012
2. **Chiorean EG**: Gastrointestinal Cancers Chapter, Yearbook in Oncology 2013
3. **Chiorean, EG**, Loehrer PJ: Multidisciplinary management of recurrent colorectal cancer: potentially resectable/curable disease. *In* Colorectal Cancer: Current Multidisciplinary Oncology, Benson, A, Chakravarthy, A, Hamilton, S, and Sigurdson, E (Eds), Demos Medical Publishing, New York. 2013
4. **Chiorean EG**, Coveler AL, Grim J, Grady WM. Targeted therapies for intestinal tumors. Intestinal Tumorigenesis: mechanisms of development and progression. Yang VW, Bialkowska AB (Eds), Springer International Publishing, Switzerland 2015.

#### C. Published books, videos, software.

1. **Chiorean EG**. PBS: Healthy Body Healthy Mind TV Series: The best doctors in the world are making house calls on public television: pancreatic cancer. 2014 <http://www.hbhm.tv/programs/pancreatic-cancer/>
2. **Chiorean EG**. OncLive TV Peer Exchange: Pancreatic cancer: nab-paclitaxel compares favorably in pancreatic cancer cost-effectiveness study. 2014
3. **Chiorean EG**. Targeted Oncology: A study of nivolumab with nab-paclitaxel plus gemcitabine in pancreatic cancer. 2017 [www.TargetedOnc.com](http://www.TargetedOnc.com)
4. John Marshall, Wells Messersmith, Marwan Fakhri, Bert O'Neill, **Chiorean EG**: OncLive Peer Exchange: Evolving Strategies for Advanced Colon and Rectal Cancer. 2018 <https://www.onclive.com/peer-exchange/advanced-crc-strategies>
5. **Chiorean EG**. Pancreatic Cancer update-an enduring audio, video, podcast, web and mobile interview series for medical oncologists and other GI cancer professionals: 2018 Edition. Neil Love Research to Practice.
6. **Chiorean EG**. Treatment Approaches to Pancreatic Cancer - Pancreatic Cancer Action Network webinar 2019
7. Ko AH, **Chiorean EG**, Laheru D, Pishvaian MJ, Wang-Gillam A. Clinical Care Options: Interactive Decision Support Tool: Expert Guidance for the Treatment of Pancreatic Cancer. 2019 <https://www.clinicaloptions.com/oncology/programs/advances-in-pancreatic-cancer/idst/tool/page-1>
8. **Chiorean EG**, Chung V. Let's win! Pancreatic Cancer: Chemotherapy explained for pancreatic cancer. An affiliate of the Lustgarten Foundation for Pancreatic Cancer Research. 2019 <https://letswinpc.org/managing-pancreatic-cancer/2019/12/27/chemotherapy-against-pancreatic-cancer/>
9. **Chiorean EG**. OncLive 2020 Treatment of Late-Stage Colorectal Cancer, ASCO Resource Stratified Guidelines
10. **Chiorean EG**, Herrman J, Pancreatic Cancer During COVID19. PanCan webinar 2020
11. **Chiorean EG**. Review of the SWOG S1505 study. OncLive 2020
12. **Chiorean EG**. Patient Webinar: Pancreatic Cancer. NCCN webinar 2021
13. **Chiorean EG**, Cohen S, Mogal H, Harris W, Zhen DB. OncLive 2021 Institutional Perspectives in Cancer: Gastrointestinal Malignancies
14. **Chiorean EG**, Lowy A, Herman J. ASCO Tumor Board 2021. Borderline resectable pancreatic cancer. <https://education.asco.org/product-details/borderline-resectable-pancreatic-cancer-tumor-board>
15. **Chiorean EG**, Philip PA. Podcast: PARP inhibition in the treatment of pancreatic cancer: current and future perspectives on personalized therapy

<https://www.clinicaloptions.com/oncology/programs/2021/parp-inhibition-pancreatic-cancer/podcasts/podcast>

16. **Chiorean EG.** NRG1 testing and targeted therapy in pancreatic cancer. OncLive2024.

#### D. Other Publications

1. **Chiorean EG,** Ng J. Panelists debate concerns, controversies surrounding treatment of GI cancers. ASCO Post 2017
2. **Chiorean EG.** Cabozantinib is superior to placebo in second-line treatment of advanced hepatocellular carcinoma. ASCO Post 2018
3. **Chiorean EG:** Gemcitabine and *nab*-paclitaxel should not be used in the adjuvant treatment of pancreatic cancer. HemOnc Today 2020.
4. **Chiorean EG,** Chamberlin M: ASCO Releases Resource-Stratified Late-Stage Colorectal Cancer Guideline. ASCO Post 2020.
5. **Chiorean EG.** ASCO guidelines take global view of late-stage colorectal cancer. MDedge Hematology and Oncology, Federal Practitioner, AVAHO 17 March 2020
6. NCCN Guidelines for Patients<sup>®</sup>: Pancreatic Cancer, Version 2021 – lead medical oncologist contributor.
7. **Chiorean EG.** CodeBreak 100: Sotorasib shows activity in KRAS G12C-mutated pancreatic cancer. Expert Point of View. ASCO Plenary Series. The ASCO Post, March 25, 2022; vol 13; 5.
8. **Chiorean EG.** Gastrointestinal Oncology Almanac: CodeBreak100: Sotorasib in KRAS G12C mutated pancreatic cancer. The ASCO Post Supplement March 2022. Ascopost.com.
9. King G, **Chiorean EG.** Exploring Perioperative Therapy in Pancreatic Cancer. ASCO Daily News June 2022 <https://dailynews.ascopubs.org/doi/10.1200/ADN.22.201014/full/>
10. **Chiorean EG.** Updates in pancreatic cancer. USA Today July 6, 2022; <https://www.usatoday.com/story/news/2022/07/06/doctors-hope-treatments-pancreatic-cancerfdg-g/7538295001/>
11. **Chiorean EG.** Seattle Magazine July 2022: They are Here to Save Your Life. Featured among eight researchers from Fred Hutchinson Cancer Center with impactful research and discoveries in progress against cancer. <https://seattlemag.com/they-re-here-save-your-life>
12. **Chiorean EG.** Feature GI Cancers: Discovering fusions requires more than DNA testing in GI cancers. OncLive.com 2024; 25(1): 35-36.
13. **Chiorean EG.** PER Spotlight “Turning Up the Heat on “Immune-Cold” GI Tumors. Targeted Therapies in Oncology 2024; 13(1): 36.
14. **Chiorean EG,** Del Chiaro M, Tempero MA, Malafa MP, Benson III AB, Cardin DB, Christensen JA, Chung V, Czito B, Dillhoff M, Donahue TR, Dotan E, Fountzilias C, Glazer ES, Hardacre J, Hawkins WG, Klute K, Ko AH, Kunstman JW, Lim K, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Poultsides G, Reddy S, Reyngold M, Scaife C, Shen J, Shergill A, Truty MJ, Vollmer Jr. C, Wolff RA, Wolpin BM, Awotiwon A, Darlow S, McCullough B, Ramakrishnan S. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Ampullary Adenocarcinoma v.2.2024. Accessed 08/02/24.
15. Tempero MA, Malafa MP, Basturk O, Benson III AB, Cardin DB, **Chiorean EG,** Christensen JA, Chung V, Czito B, Del Chiaro M, Dillhoff M, Donahue TR, Fountzilias C, Glazer ES, Hardacre J, Klute K, Ko AH, Kunstman JW, Lim K, LoConte N, Lowy AM, Masood A, Moravek C, Nakakura EK, Narang AK, Nardo L, Obando J, Polanco PM, Poultsides G, Reddy S, Reyngold M, Scaife C, Shergill A, Truty MJ, Vollmer Jr. C, Weinberg D, Wolff RA, Wolpin BM, Awotiwon A, Ramakrishnan S. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) for Pancreatic Adenocarcinoma V.2.2025. Accessed 02/03/2025
16. Fung A, Zaheer A, Porter KK, Bashir MR, Cash BD, **Chiorean EG,** Choi Y, Ejaz A, Gage KL, Russo GK, Small W, Smith EN, Thakrar KH, Vij A, Wahab SA, Kim DH. Screening,

locoregional assessment, and surveillance of pancreatic ductal adenocarcinoma. American College of Radiology (ACR) Appropriateness Criteria 2025

#### E. Manuscripts Submitted

1. Gottschalk Z, Demirci RA, Chen DL, **Chiorean EG**, Cohen SA. Peptide receptor radionuclide therapy in pancreatic neuroendocrine neoplasms metastatic to the brain: a case series. *Pancreas*
2. Anbil S, Seewald NJ, **Chiorean EG**, Hamilton EP, Hussein M, Kasi P, Malik Z, Reeves JA, Schwartz GK, Shapiro G, Lin KK, Craib M, Connor C, Giordano H, Maloney L, McLachlan K, Kwan T, Tukachinsky H, Schrock AB, Wang S, Sokol ES, Decker B, Nathanson KL, Domchek SM, Reiss KA. LODESTAR: A Single Arm Phase II Study of Rucaparib in Solid Tumors with Pathogenic Germline or Somatic Variants in Homologous Recombination Repair Genes. *Clin Cancer Res* 2025
3. Hayman JS, Torti GM, Park JO, Krane MK, Kim EY, **Chiorean EG**, Cohen SA, Coveler A. Primary Tumor Complications in Metastatic Rectal Cancer Patients with Retained Primary Tumors. *Clin Colorectal Cancer* 2025
4. King GG, Baker KK, Coveler AL, Harris WP, Cohen SA, Shankaran S, Zhen DB, Safyan RA, Lee HH, Alidina A, Hensel J, Hibbert R, Durm GA, LaFary YC, Younger A, Kugel S, Collisson E, Konnick E, Redman MW, Schneider BP, Pritchard CC, Shahda SS, **Chiorean EG**. Phase Ia/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers. *Cancers* 2025.
5. **Chiorean EG**, Zhen DB, Whittle M, George B, Hochster H, Coveler AL, Ritch P, Hendifar A, Dragovich T, Safyan RA, King GG, Harris WP, Dion B, Stoll-D'Astice A, Lee A, Thorsen S, Kugel S, Rosenthal A, Hingorani SR. Phase II Study of Pegvorhialuronidase Alfa and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. *Cancer Res Commun* 2025

#### F. Abstracts

1. Mattson J, Estry D, Rea E, Farrah D, Wolak H, Westley S, **Chiorean EG**, O'Neill WW, Chen J. Monoclonal Antibody MDP-1 Defines a Non-RGD-dependent Epitope near the HPA-1 Domain on Platelet GpIIb Involved in Fibrinogen Binding, Aggregation and Clot Retraction. *Blood*. 1997; 90, 3015a
2. **Chiorean EG**, Jaiyesimi I, Mattson J. AML in the Elderly: Experience in an Academic Community Hospital. *Blood*. 1998; 92 # 3894a
3. **Chiorean EG**, Olsen K, Dylla S, Brungard K, Miller JS. BCR/ABL Alters the Function and Influences Receptor Expression of Natural Killer Cells. *Blood* 2001; 98 # 78a Poster American Society of Hematology
4. **Chiorean EG**, DeFor T, Blazar B, Weisdorf BJ, McGlave PB, Verfaillie CM, Miller JS. Effect of Donor Chimerism on the GVHD Risk and Response to DLI for Relapsed Hematological Malignancies after Allogeneic Transplantation. *Blood* 2001; 98(11) 5232a
5. **Chiorean EG**, Olsen K, Dylla S, Lund T, Miller JS. BCR/ABL Alters the Function of NK Cells. *Experimental Hematology* 2001; 29(8) # 242a Oral presentation International Society of Hematology, Tokyo, Japan
6. **Chiorean EG**, Dragovich T, Hamm J, Langmuir VK, Kroll S, Jung DT, Colowick AB, Loehrer PJ. Glufosfamide plus gemcitabine in advanced solid tumors: preliminary results of a Phase 1/2 trial. 2006 ASCO GI Cancers Symposium 239a Poster.
7. Setlik RF, **Chiorean EG**, Mulkerin D, Preston G, Dufresne T, Petrone ME, Nathan FE, D. Greene, Takimoto CH, Camacho LH. Phase I study of the effects of hepatic impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer. *J Clin Oncol* 2006; 24 (18S): 2045a Poster ASCO

8. Hong DS, Galsky M, **Chiorean E**, Mulkerin D, Greene D, Nathan FE, Petrone M, Camacho L. Phase I study of the effects of renal impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer. *J Clin Oncol* 2006; 24 (18S): 2044a. Poster ASCO
9. Loehrer PJ, Yiannoutsos CT, Dropcho S, Burns M, Helft P, **Chiorean EG**, Nelson RP. A Phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. *J Clin Oncol* 2006; 24 (18S): 7079a. Poster ASCO
10. **Chiorean EG**, Dragovich T, Hamm J, Barrios CH, Gorini CF, Langmuir VK, Kroll S, Tidmarsh GT, Colowick AB, Loehrer PJ. Glufosfamide plus gemcitabine in pancreatic adenocarcinoma: preliminary results of a phase 2 trial. *J Clin Oncol* 2007; 25:15005a. Poster ASCO
11. Sweeney C, Verschraegen C, **Chiorean G**, Lee F, Jones S, Tye L, Bello A, Chao R, Burris H III. A phase I dose escalation study of sunitinib plus capecitabine in patients with advanced solid tumors. *J Clin Oncol* 2007; 25: 3592a. Poster ASCO 2007
12. Malireddy SR, **Chiorean EG**, Foster A, Jones D, Waddell M, Margol M, Hall S, Schneider B, Sweeney CJ. A phase I dose escalation trial of the VEGFR tyrosine kinase inhibitor, PTK787/ZK222584 (PTK/ZK), used in combination with paclitaxel in patients with advanced solid tumors with pharmacokinetic analysis. *J Clin Oncol* 2007; 25: 14012a. Poster
13. **Chiorean EG**, Dragovich T, Hamm J, Barrios C, Gorini CFN, Langmuir VK, Kroll S, Tidmarsh GT, Colowick AB, Loehrer PJ. Glufosfamide plus Gemcitabine in pancreatic adenocarcinoma: results of a Phase 2 trial. ECCO Proceedings. ECCO meeting 2007, Barcelona, Spain- Poster
14. **Chiorean EG**, Hurwitz H, Cohen R, Temmer E, Schwartz J, Wang G, Fox F, Rowinsky E, Youssoufian H. Phase I dose-escalation study of the anti-VEGFR-2 fully human IgG<sub>1</sub> MAb IMC-1121B administered every other week or every 3 weeks in patients with advanced cancers. AACR EORTC NCI Molecular Targets and Cancer Therapeutics Meeting, San Francisco, CA 2007; B15a. Poster
15. Chan E, O'Dwyer P, Gabrail N, **Chiorean G**, Zuomei L, Tawashi M, Laille E, Drouin M, Martell R, Hurwitz H. Phase I Trial of the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103 in Combination with Gemcitabine in Patients With Refractory Solid Tumors. ASCO GI Cancers Symposium 2008; 181a. Poster
16. **Chiorean EG**, Sanghani S, Cardenes H, Schiell M, Menggang Y, Shen J, LeBlanc J, Robb B, Harvey J, Loehrer P. Phase II trial of neoadjuvant capecitabine plus irinotecan followed by combined modality capecitabine and radiation therapy for patients with locally advanced rectal cancer: a Hoosier Oncology Group study. ASCO GI Cancers Symposium 2008; 460a Poster
17. Hammoud ZT, Zhao Q, **Chiorean EG**, Badve S., Li L, Rieger K, Kesler K. Gene expression analysis of esophageal carcinoma. ASCO GI cancers Symposium 2008; 85a. Poster
18. LoRusso PM, Hurwitz HI, **Chiorean EG**, Jewel RC, Lampkin T, Bachman K, Kumar R, Lebowitz PF, Weber BL. AKT Inhibitor GSK690693-preliminary results from the first-in-human study. AACR 2008 Meeting 9441a, LB 68. Poster
19. **Chiorean EG**, Sweeney CJ, Verschraegen CF, Lee FC, Jones S, Rabinowitz I, Tye L, Bello A, Chao R, H. A. Burris, III Tolerability/safety of sunitinib on schedule 2/1 in combination with capecitabine in patients with advanced solid tumors: a phase I dose-finding study. *J Clin Oncol* 2008 3562a. Poster ASCO 2008
20. H. Hurwitz, B. Nelson, P. J. O'Dwyer, **E. G. Chiorean**, N. Gabrail, Z. Li, E. Laille, M. Drouin, M. L. Rothenberg, E. Chan. Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors. *J Clin Oncol* 2008 4625a. Poster ASCO 2008
21. Sweeney C, **Chiorean EG**, Mita M, Papadopoulos K, Silver B, Freed M, Gokemeijer J, Eaton C, Furfine E, Tolcher A. Phase 1 Study of CT-322, first adnectin protein therapeutic

- and potent inhibitor of VEGFR-2, in patients with advanced solid tumors J Clin Oncol 2008; 3523 a. Oral presentation ASCO 2008.
22. **Chiorean EG**, Sweeney C, Youssoufian H, Fox F, Katz T, Rowinsky E, Amato R. Phase I study of IMC-3G3, an IgG1 monoclonal antibody targeting platelet-derived growth factor alpha (PDGFR $\alpha$ ) in patients with advanced solid malignancies. Eur J Cancer 2008; 6 (12): 511a. Poster AACR/NCI/EORTC Meeting, Geneva, Switzerland
  23. Serkova NJ, Spratlin J, Eckhardt SG, Milestone B, **Chiorean EG**, Youssoufian H, Fox F, Rowinsky E, Cohen RB. DCE-MRI endpoints reveal decreased tumor vascularity in patients with liver metastases: a Phase I dose escalating study with IMC-1121B. Eur J Cancer 2008; 6 (12): 41a Poster AACR/NCI/EORTC 2008
  24. Weiss GJ, Infante JR, Borad M, Langmuir VK, Kroll S, Jung D, Tibes R, **Chiorean EG**, Jones SF, Burris HA. A first-in-man phase I study of TH-302, a hypoxia-activated cytotoxic prodrug. Eur J Cancer 2008; 6 (12): 412a. Poster AACR/NCI/EORTC 2008
  25. **Chiorean EG**, Mahadevan D, W. B. Harris, D. D. Von Hoff, A. E. Younger, D. M. Rensvold, C. F. Shelton, B. T. Hennessy, J. R. Garlich, R. K. Ramanathan. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J Clin Oncol 2009; 27: 2558 abstract ASCO 2009 poster
  26. Bendell JC, Weiss GJ, Infante JR, **Chiorean EG**, Borad M, Tibes R, Jones SF, Langmuir VK, Kroll S, Burris HA. Final results of a phase I study of TH-302, a hypoxia-activated cytotoxic prodrug (HAP). J Clin Oncol 2009; 27: 2573 abstract. ASCO 2009 poster
  27. Patnaik A, **Chiorean EG**, Tolcher A, Papadopoulos K, Beeram M, Kee D, Waddell MJ, Gilles E, Buchbinder A. EZN-2968, a novel hypoxia-inducible gfactor-1alpha messenger RNA antagonist: results of a phase I, PK dose escalation study of daily administration in patients with advanced malignancies. J Clin Oncol 2009; 2564 abstract. ASCO 2009 poster
  28. Lall CG, Patel A, **Chiorean EG**, Tann M, Rajesh A, Aisen AM. Recognizing post chemotherapy changes in the abdomen: imaging and perspectives. RSNA 2009 meeting educational exhibit.
  29. S. Kleyman, H. Cardenes, T. Howard, M. Yu, PJ Loehrer, A. Nakeeb, K. Lillemoe, **EG Chiorean**. Is adjuvant gemcitabine-based chemoradiation superior to gemcitabine alone for resected pancreatic adenocarcinoma? The Indiana University experience. ASCO GI Cancers Symposium 2010; 212 abstr. Poster
  30. Anderson ST, Cardenes H, Akisik F, DeWitt J, Johnston EL, Spittler J, Clark R, Howard T, Zeng Y, Calley C, Schneider B, **Chiorean EG**. Phase I study of gemcitabine with sorafenib and radiotherapy in patients with locally advanced unresectable pancreatic adenocarcinoma. ASCO GI Cancers Symposium 2010; 225 abstr. Poster
  31. Ramasubbaiah R, Picus J, Bufill J, Loehrer PJ, Johnston EL, Flynn J, Currie C, Tong Y, Yu M, **Chiorean EG**. Interim analysis of a phase II trial of erlotinib (E) in combination with docetaxel (D) in advanced hepatocellular (HCC) and biliary tract carcinomas (BTC): Hoosier Oncology Group GI06-101. ASCO GI Cancers Symposium 2010; 251 abstract; poster
  32. Borad M, Mita A, **Chiorean EG**, Infante J, Langmuir VK, Eng C, Kroll S, Curd S. TH-302, a tumor selective hypoxia-activated prodrug, in gastrointestinal cancers. ASCO GI Cancers Symposium 2010; 213 abstr
  33. O'Dwyer PJ, Gallagher M, Nguyen B, Waddell MJ, **Chiorean EG**. Phase I accelerated dose-escalating safety and pharmacokinetic study of GGTI-2418, a novel geranylgeranyltransferase I inhibitor in patients with refractory solid tumors. Targeted Advanced Therapies Meeting 2010; poster.
  34. Anderson S, Cardenes H, Akisik F, Johnston EL, Clark R, Perkins S, Johnson CS, Loehrer P, Schneider B, **Chiorean EG**. Phase I study of sorafenib with gemcitabine-based radiotherapy in patients with locally advanced unresectable pancreatic adenocarcinoma. ASCO 2010; abstract 4139; poster.

35. **Chiorean EG**, Matei D, Younger AE, Funke JM, Waddell MJ, Jones DR, Hahn N, Perkins S, Sandrasegaran K, Sweeney CJ. Phase I study of sorafenib with bevacizumab and paclitaxel in patients with refractory solid tumors. ASCO 2010; abstract 3043; poster
36. Chawla SP, Taberero J, Kindler HK, **Chiorean EG**, LoRusso P, Hsu M, Haddad V, Bach BA, Baselga J. Phase I evaluation of the safety of conatumumab (AMG655) in combination with AMG 479 in patients with advanced refractory solid tumors. ASCO 2010; 3102 abstract; poster.
37. Beatty GL, **Chiorean EG**, Torigian DA, Teitelbaum UR, Sun W, Fly KD, Huhn RD, Vonderheide RH, O'Dwyer PJ. A phase I study of CD40 agonist monoclonal antibody (CP-870,893) with gemcitabine in pancreatic cancer. ASCO 2010; 2539 abstract; poster.
38. H. Cardenes, S. Sanghani, M. Burns, B. Robb, D. Hinkle, C. Johnson, M. Yu, C. Currie, P. Loehrer, **E. Chiorean**. Phase II trial of neoadjuvant capecitabine with irinotecan followed by capecitabine-based chemoradiotherapy for patients with locally advanced rectal cancer (LARC): A Hoosier Oncology Group Study. ASTRO 2010; abstract 362; oral presentation.
39. Owusu-Sarfo K, Asiago V, Shanaiah N, Nagan Gowda GA, Xi B, **Chiorean G\*\***, Rafferty D. <sup>1</sup>H NMR based metabolic profiling of serum for the detection of pancreatic cancer. ASCO GI Cancers Symposium 2011; poster
40. Hocevar BA, **Chiorean EG**, Kamendulis LM, Perkins S, Johnston EL, Li L, Klaunig JE. Contribution of environment and genetics to oxidative stress in pancreatic cancer patients. ASCO GI Cancers Symposium 2011; poster
41. Khawaja MR, Zyromski N, Yu M, Cardenes H, Schmidt CM, Sandusky G, Howard T, **Chiorean EG**. Effect of body mass index on outcomes after surgical resection and adjuvant therapy for patients with pancreatic cancer. ASCO GI Cancers Symposium 2011; poster
42. Myre B, Picus J, Bufill J, Harb W, Yu M, Burns M, Spittler J, Zeng Y, Currie C, **Chiorean EG**. Phase I/II study of everolimus (RAD001) with irinotecan and cetuximab in 2<sup>nd</sup> line metastatic colorectal cancer: Hoosier Oncology Group GI05-102. ASCO GI Cancers Symposium 2011; poster
43. Hardacre JM, Mulcahy MF, Small W, Talamonti M, Obel JC, Rocha Lima CMS, Safran H, Lenz HJ, **Chiorean EG**, Link CJ. Addition of algenpantucel-I immunotherapy to standard adjuvant therapy may improve survival in resected pancreas cancer patients. *ASCO GI Cancers Symposium 2011*; poster
44. Borad MJ, **Chiorean EG**, Molina JR, Mita AC, Infante JR, Schelman WR, Traynor AM, Vlahovic G, Mendelson DS, Reddy SG. TH-302, a tumor selective hypoxia activated prodrug, complements the clinical benefits of gemcitabine in first line pancreatic cancer. *ASCO GI Cancers Symposium 2011*; poster.
45. **Chiorean EG**, Sausville E, Heath E, Weise A, Gomez-Navarro J, Venkatakrishnan K, Sankoh S, Wu JT, Cortez M, LoRusso P. Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in patients with advanced cancer: Updated results and assessment of human CSF distribution. *ASCO 2011*; poster-discussion abstract 2538.
46. Khawaja MR, Younger A, Funke JM, Waddell MJ, Jones DR, Pollok K, Prasad NK, Berry W, Sandusky G, **Chiorean EG**. Phase I study of everolimus (RAD001) and AMG 479 in patients with advanced solid tumors and colorectal cancer (CRC). *ASCO 2011*; poster; abstract TPS157
47. Shahda S, Yu M, Picus J, Bufill JA, Harb WA, Burns M, Spittler AJ, Flynn J, Zeng Y, Vance GH, Wu J, Currie CR, Loehrer PJ, **Chiorean EG**. Phase I study of everolimus (RAD001) with irinotecan (Iri) and cetuximab (C) in second-line metastatic colorectal cancer (mCRC): HoosierOncology Group GI05-102—Final report. ASCO 2011; poster; abstract 3587.
48. Mahadevan D, **Chiorean EG**, Harris W, Von Hoff DD, Younger A, Rensvold DM, Cordova F, Qi W, Shelton CF, Becker MD, Garlich JR, Ramanathan RK. Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies. *ASCO 2011*; poster discussion, abstr 3015

49. Borad M, Sigal DS, Uronis H, Stephenson J, Bahary N, Rarick M, DeMarco LC, Finnegan T, **Chiorean EG**, Ryan DP, Cohn AL, Ulrich B, Harish V, Anderes E, Ma W, Yu P, Siniscope F, Eng C, Sunkara U, Reddy S. Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 vs gemcitabine alone in previously untreated patients with advanced pancreatic cancer. *ASCO 2011*; poster; abstract TPS176.
50. Chen N, Sharma S, **Chiorean EG**, Chawla S, Read W, Gorbaty M, Mita A, Yung L, McNally R, Renschler MF. Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety of amrubicin in patients with advanced solid tumors. *ASCO 2011*; poster; abstr 7073.
51. Martell RE, **Chiorean EG**, et al. Phase I study of the anti-VEGFR-3 monoclonal antibody IMC-3C5 in subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy is available. *ASCO 2011*; poster; abstract TPS150.
52. Heusner-Banks K, Sandrasegaran K, Kim S, Moore LT, Tann M, Verma S, Lamba R, Bhosale P, **Chiorean EG**. What the radiologist needs to know about “mabs” and “nibs”- the new wonder anticancer drugs. Radiological Society of North America (RSNA) Scientific Congress and Annual Meeting, 2011, Chicago, Ill; Poster.
53. Borad MJ, Reddy S, Bahary N, Uronis H, Sigal DS, Cohn AL, Schelman WR, Stephenson J, **Chiorean EG**, Rosen PJ, Ulrich B, Dragovich T, Del Prete S, Rarick M, Eng C, Kroll S, Ryan D. A randomized crossover phase 2 study of the safety and efficacy of two dose levels of TH-302 in combination with gemcitabine compared with gemcitabine alone in previously untreated patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma. *AACR 2012* oral presentation.
54. Tabernero J, Cervantes A, Gordon M, **Chiorean EG**, Burris HA, Macarulla T, Perez-Fidalgo A, Martin M, Jessen K, Liu Y, Le T, Rommel C, Berk GI, Bui LA, Infante JR. A phase 1, open-label, dose-escalation study of oral mammalian target of rapamycin (TORC1/2) inhibitor MLN0128 (INK128) administered by intermittent dosing regimens in patients with advanced malignancies. *AACR 2012*; oral presentation.
55. Hardacre JM, Mulcahy MF, Small W, Talamonti MS, Obel JC, Rocha Lima CMS, Safran H, Lenz HJ, **Chiorean EG**, Vahanian N, Link CJ. Addition of algenpantucel-L immunotherapy to standard of care adjuvant therapy for pancreatic cancer. *ASCO 2012*; poster; abstract
56. Mendelson DS, Rosen LS, **Chiorean EG**, Robert F, Spencer SD, Adams BJ, Alvarez D, Seon BK, Theuer CP, Gordon MS. An open label phase 1b dose escalation study of TRC105 combined with standard dose bevacizumab for advanced solid tumors. *ASCO 2012* poster; abstr 3034
57. Sarantopoulos J, **Chiorean EG**, Stephenson J, Burris HA, Mahalingam D, Youngers A, Ayan-Oshodi M, Baldwin J, Infante JR. Pharmacokinetic study of enzastaurin in cancer patients with varying degrees of hepatic dysfunction, EORTC-NCI-AACR Molecular 2012, Dublin, Ireland oral presentation
58. Von Hoff DD, Ervin T, Arena FP, **Chiorean EG**, Infante J, Moore M, Seay T, Tjulandin SA, Ma W, Saleh M, Harris M, Reni M, Ramanathan R, Tabernero J, Hidalgo M, Van Cutsem E, Goldstein D, Wei X, Iglesias J, Renschler M. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas. *ASCO GI Cancers Symposium 2013* oral presentation.
59. Von Hoff DD, Ervin T, Arena FP, **Chiorean EG**, Infante J, Moore M, Seay T, Tjulandin SA, Ma W, Saleh M, Harris M, Reni M, Ramanathan R, Tabernero J, Hidalgo M, Van Cutsem E, Goldstein D, Wei X, Iglesias J, Renschler M. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas. *ASCO 2013* oral presentation, 4005a.
60. **Chiorean EG**, Von Hoff DD, Ervin TJ, Arena FP, Infante JR, Bathini VG, Evans Wood T, Mainwaring PN, Muldoon RT, Clingan PR, Kunzmann V, Ramanathan RK, Tabernero J, Glodstein D, Ko A, Lu B. CA19-9 decrease at 8 weeks as a predictor of overall survival in a

- randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. ASCO 2013 poster 4058a.
61. Rossi GR, Hardacre JM, Mulcahy MF, Talamonti MS, Obel JC, Rocha Lima CM, Safran H, Lenz HJ, **Chiorean EG**, Vahanian NN, Link CJ. Algenpantucel-1 immunotherapy for pancreatic cancer induces anti-mesothelin antibody titers that positively correlate with improved overall survival. ASCO 2013 oral presentation, 3007a
  62. Moore MJ, Von Hoff DD, Ervin TJ, Arena FP, **Chiorean EG**, Infante JR, Kon JK, Biakhov MY, Hingorani SR, Ganju V, Weeks CD, Scheithauer W, Ramanathan RK, Tabernero J, Goldstein D, Wei X, Romano A. Prognostic factors of survival in a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic pancreatic cancer. ASCO 2013 poster 4059a.
  63. Jalal SI, Strother RM, Sandusky G, Prasad N, Berry W, Jones DR, Younger AE, Funke JM, Detty T, Althouse S, Perkins S, **Chiorean EG**. Phase I study of everolimus and ganitumab in patients with advanced solid tumors ASCO 2013 poster discussion, 2529a J Clin Oncol 2013; 31 (suppl; abstr 2529)
  64. Jimeno A, LoRusso P, Strother RM, Diamond J, Younger AE, Adriaens L, Liu L, Kao R, Dicioccio T, **Chiorean EG**. A phase I first-in-human study of REGN421 (R), a fully-human Delta-like Ligand 4 (Dll4) monoclonal antibody, in patients with advanced solid tumors. ASCO 2013 oral presentation, 2502a
  65. Gordon MS, Rosen LS, Robert F, Matei DE, Mendelson DS, Goldman JW, **Chiorean EG**, Seon BK, Alvarez D, Adams BJ, Theuer CP. A phase 1b dose-escalation study of TRC105 (Anti-Endoglin Antibody) in combination with bevacizumab for advanced solid tumors. ASCO 2013 poster, 3059a
  66. Goodman B, Calley C, Maluccio M, Helft P, **Chiorean EG**, Cardenes HR. Stereotactic body radiotherapy response and local control rates for hepatic oligometastases. ASCO 2013 poster, 3546a.
  67. **Chiorean EG**, Whiting S, Binder G, Dranitsaris G, Manax V. Cost effectiveness of nab-Paclitaxel + Gemcitabine vs. Erlotinib + Gemcitabine in Metastatic Pancreatic Cancer. ASCO GI Cancers Symposium 2014 poster. J Clin Oncol 2014; 32 suppl 3; abstr 353
  68. Rossi G, Rocha Lima CM, Hardacre JM, Mulcahy MF, Talamont MS, Obel JC, Safran H, Lenz HJ, **Chiorean EG**, Vahanian NN, Link CJ. Correlation of anti-calreticulin antibody titers with improved survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer. ASCO 2014 poster highlights session; J Clin Oncol 2014;325s (suppl; abstr 3029)
  69. Lin EH, Patel SA, Chou J, Kim EY, Shankaran V, Coveler AL, Harris WP, Park JO, Fichera A, Mann GN, **Chiorean EG**, Pritchard CC, Sinanan M, Upton M, Storer B, Yeung RS, Li L. A phase II trial of maintenance ADAPT therapy targeting colon cancer stem cells in patients with metastatic colorectal cancer. ASCO 2014 poster; J Clin Oncol 2014; 325s (suppl abstr TPS3650)
  70. Coveler AL, Pillarisetty VG, Gyurkey G, Koh WJ, Upton M, Cuevas C, Gooley T, **Chiorean EG**, Shankaran V, Harris WP, Park JO, Mann GN, Byrd DR, Balas S, Whiting SH. A phase II study of perioperative therapy for patients with resectable and borderline-resectable pancreatic adenocarcinoma. ASCO 2014 poster; J Clin Oncol 2014; 325s (suppl abstr 4120).
  71. Kalyan A, Kircher S, Denlinger CS, Berlin J, Mulcahy MF, Cohen SJ, **Chiorean EG**, Zalupski M, Benson AB, Nimeiri HS. A phase I multicenter study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors. ACO GI 2015 poster; J Clin Oncol 2015; 33 (suppl 3; abstr TPS492)
  72. **Chiorean EG**, Picus J, Breen T, Ansari RH, Harb WA, Burns M, Spittler AJ, Loehrer PJ. Phase I/II study of everolimus with irinotecan and cetuximab in 2nd line metastatic colorectal cancer: Hoosier Cancer Research Network GI05-102. ASCO 2015 poster; J Clin Oncol 2015; 33 (suppl; abstr 3618)

73. Saif WM, Knost JA, **Chiorean EG**, Kambhampati SRP, Yu D, Pytowski B, Qin A, Kauh JS, O'Neil BH. Phase 1 study of anti-VEGF receptor-3 (VEGFR-3) monoclonal antibody LY3022856/ IMC-3C5 (3C5) ASCO 2015 poster; J Clin Oncol 2015; 33 (suppl abstr 3530)
74. McWilliams RR, Ko AH, **Chiorean EG**, et al. A phase 1b dose escalation study of PRI-724, a CBP-beta-catenin modulator plus gemcitabine in patients with advanced pancreatic adenocarcinoma as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol 2015; 33 (suppl; abstr e15270)
75. **Chiorean EG**, Wan Y, Whiting S, Margunato-Debay S, Botteman M. Impact of nab-paclitaxel plus gemcitabine vs gemcitabine alone on Karnofsky performance status (KPS) in metastatic pancreatic cancer patients with good or poor performance status at baseline: a post-hoc analysis of the MPACT trial. ESMO/ECCO 2015 Vienna, abstract 2346
76. Goldstein D, **Chiorean EG**, Tabernero J, et al. Outcome of second-line treatment following nab-paclitaxel + gemcitabine or gemcitabine alone for metastatic pancreatic cancer. GI Cancers Symposium 2016; J Clin Oncol 2016; 34; suppl 4S; abstr 333.
77. Nimeiri HS, Pai GS, **Chiorean EG**, et al. Safety and efficacy of combination of temozolomide and pazopanib in patients with advanced pancreatic neuroendocrine tumors. J Clin Oncol 34, 2016 (suppl; abstr e15662)
78. Ko AH, **Chiorean EG**, Kwak EL, Lenz HJ, Nadler PI, Wood DL, Fujimori M, Inada T, Kouji H, McWilliams RR. Final results of a phase 1b dose-escalation study of PRI-724, a CBP/beta-catenin modulator, plus gemcitabine (GEM) in patients with advanced pancreatic adenocarcinoma (APC) as second-line therapy after FOLFIRINOX or FOLFOX. J Clin Oncol 2016; 34 (suppl; abstr e15721)
79. Hochster H, Wainberg ZA, Gutierrez M, Waterhouse DM, **Chiorean EG**, George B, Ko A, Manax V, O'Dwyer PJ. Phase 1 study of nivolumab plus nab-paclitaxel with and without gemcitabine in pancreatic cancer: safety evaluation of patients treated with nivolumab and nab-paclitaxel in arm A. AACR Pancreatic Cancer 2016: Advances in Science and Clinical Care; poster
80. Chang AE, Shahda S, Harris WP, Cohen S, O'Neill B, Coveler AL, Gadi VK, Hibbert R, Lee HH, Younger A, McCormick K, Pritchard CC, Redman MW, **Chiorean EG**. Phase I/Ib multicenter study of irreversible EGFR/HER2 tyrosine kinase inhibitor afatinib in combination with capecitabine for advanced solid tumors and pancreatico-biliary cancers. ASCO GI Cancers Symposium 2017; J Clin Oncol 2017; 35 (suppl 4S, abstr TPS515)
81. Wainberg ZA, Hochster HS, George B, Gutierrez M, Emery Johns M, **Chiorean EG**, Kwak EL, Kalyan A, Manax V, Ye M, Chen T, Trunova N, O'Dwyer PJ. Phase I study of nivolumab + nab-paclitaxel +/- gemcitabine in solid tumors: interim results from the pancreatic cancer cohorts. ASCO GI Cancers Symposium 2017; J Clin Oncol 2017; 35 (suppl 4S, abstr 412)
82. Torti GM, Park JO, **Chiorean EG**, Kim EY, Cohen SA, Coveler AL. Retrospective review of outcomes in patients with synchronous metastatic rectal cancer receiving initial non-surgical management. ASCO GI Cancers Symposium 2017; abstr 797; J Clin Oncol 2017; 35 (suppl 4S, abstr 797)
83. Potts SJ, Dean EJ, Polikoff J, Pacey S, **Chiorean EG**, Chee CE, Sigal D, Aslam M, Pauwels P, Christiansen JH, Multani PS, Lamoureux J, Murphy D. Detecting NTRK, ROS1, and ALK gene fusions in gastrointestinal tumor patients. ASCO GI Cancers Symposium 2017; J Clin Oncol 2017; 35 (suppl 4S; abstr 619)
84. **Chiorean EG**, Wan Y, Margunato-Debay S, Botteman M, Goldstein D, Von Hoff DD. Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer. NCCN 2017 Annual Conference; abstr/poster
85. **Chiorean EG**, Nanda S, Hochster H, Thornton D, Klise S. A phase II study of abemaciclib as a monotherapy and in combination with other agents in patients with previously treated

- metastatic pancreatic ductal adenocarcinoma (PDAC). ASCO 2017 poster TPS4150 J Clin Oncol 2017; 35: suppl abstr TPS4150
86. **Chiorean EG**, McDonough S, Philip PA, Swisher E, Pishvaian M, Guthrie K, Lowy AM, Hochster H. Randomized phase II study of 2nd-line FOLFIRI versus modified FOLFIRI with PARP inhibitor ABT-888 (veliparib) (NSC-737664) in metastatic pancreatic cancer (mPC): SWOG S1513. ASCO 2017 poster TPS4147 J Clin Oncol 2017; 35: suppl abstr TPS4147
  87. Wang J, Nemunaitis J, **Chiorean EG**, LoRusso P, Courtney K, et al. Ongoing phase 1 trial of SL-801, a novel XPO-1 inhibitor in patients with advanced solid tumors; interim results. ESMO 2017 abstract/poster
  88. Bekaii-Saab TS, Ou FS, Anderson DA, Ahn DH, Boland PM, Ciombor KK, Jacobs NL, Desnoyers RJ, Cleary JM, Meyers JP, **Chiorean EG**, Pedersen K, Barzi A, Sloan J, McCune JS, Lacouture, Lenz HJ, Grothey A. Regorafenib dose optimization study (ReDOS): a randomized phase II trial to evaluate dosing strategies and preemptive skin treatment for regorafenib in refractory metastatic colorectal cancer –an ACCRU study. 2018 ASCO GI Cancers Symposium. J Clin Oncol 2018; 36 (suppl 4s; abstr 611)
  89. Bekaii-Saab TS, Ou FS, Anderson DA, Ahn DH, Boland PM, Ciombor KK, Jacobs NL, Desnoyers RJ, Cleary JM, Meyers JP, **Chiorean EG**, Pedersen K, Barzi A, Sloan J, McCune JS, Lacouture, Lenz HJ, Grothey A. Regorafenib dose optimization study (ReDOS): randomized phase II trial to evaluate escalating dosing strategy and preemptive topical steroids for regorafenib in refractory metastatic colorectal cancer –an ACCRU Network study. Ann Oncol 2018; 29 (suppl 5: abstr O-014)
  90. Ramanathan RK, McDonough S, Philip PA, Hingorani nSR, Lacy J, Kortmansky JS, Thumar J, **Chiorean EG**, Shields AF, Behl D, Mehan PT, Gaur R, Seery T, Guthrie KA, Hochster HS. A phase IB/II randomized study of mFOLFIRINOX (mFFOX) + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus mFFOX alone in patients with good performance status metastatic pancreatic adenocarcinoma (mPC): SWOG S1313. 2018 ASCO GI Cancers Symposium; J Clin Oncol 2018; 36 suppl 4S, abstr 208
  91. Bhava MA, Kircher SM, Kalyan A, Berlin J, Mulcahy MF, Cohen SJ, Denlinger CS, **Chiorean EG**, Sahai V, Zalupski M, Rademaker A, Benson AB, Nimeiri H. A phase I/II study of the combination of temozolomide and pazopanib in advanced pancreatic neuroendocrine tumors. ASCO 2018; J Clin Oncol 2018; 36: suppl abstr 4096.
  92. Wang JS, Barve MA, **Chiorean EG**, LoRusso P, Courtney KD, Qi D, Olguin A, Bullington J, Sardone M, Dunn V, Shemesh S, Chen J, Brooks C, Bauer TM. Interim results from a phase 1 trial of SL-801, a novel XPO-1 inhibitor, in patients with advanced solid tumors. ASCO 2018; J Clin Oncol 2018; 36: suppl abstr 2560.
  93. **Chiorean EG**, Cheung WY, Giordano G, Kim G, Al-Batran SE. Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in patients with advanced pancreatic cancer. ESMO 2018; Ann Oncol 2018; 29 suppl 8, abstr 724.
  94. Bauer TM, Barve M, **Chiorean EG**, et al. Interim results from a phase I trial of SL-801: a novel XPO-1 inhibitor, in patients with advanced solid tumors. ESMO 2018; Ann Oncol 2018; 29 suppl 8 abstr 428P.
  95. Sharma S, Becerra CR, Matrana MR, Alistar AT, **Chiorean EG**, Schmid AN, Grigorian B, Hou S, Desai N. A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss. 2019 ASCO GI Cancers Symposium. J Clin Oncol 2019; 37 (suppl 4; abstr TPS730)
  96. Hannan LM, Harris WP, Shankaran V, Coveler AL, Pritchard C, Zhen DB, Cohen S., Konnick EQ, **Chiorean EG**, Wong KM. Small bowel adenocarcinoma: A single center experience. 2019 ASCO GI Cancers Symposium. J Clin Oncol 2019; 37 (suppl 4; abstr 449)
  97. Wainberg ZA, Hochster HS, Kim EJH, George B, Kalyan A, **Chiorean EG**, Waterhouse DM, Gutierrez M, Parikh AR, Jain R, Carrizosa DR, Soliman HH, Bhore R, Banerjee S, Lyons L,

- Loui CU, Ong TJ, O'Dwyer PJ. Phase I study of nivolumab + nab-paclitaxel + gemcitabine in advanced pancreatic cancer. 2019 ASCO GI Cancers Symposium. J Clin Oncol 2019; 37 (suppl 4; abstr 298)
98. **Chiorean EG**, Guthrie KM, Philip A Philip, Elizabeth Swisher, Florencia Jalikis, Michael J. Pishvaian, Jordan Berlin, Marcus S Noel, J. Marie Suga, Ignacio Garrido-Laguna, Dana Cardin, Andrew M Lowy, Howard Hochster. Randomized Phase II Study of 2nd Line Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) vs FOLFIRI in Metastatic Pancreatic Cancer: SWOG S1513. ASCO 2019, J Clin Oncol 2019; 37 (suppl; abstr 4014) poster discussion.
  99. Jatoi A, Ou FS, Ahn DH, Boland PM, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen K, Barzi A, **Chiorean EG**, Heying EN, Lenz HJ, Sloan JA, Lacouture M, Grothey A, Bekaii-Saab T. Preemptive versus reactive topical clobetasol for regorafenib-induced hand-foot reactions: Results from the ReDOS trial. ASCO 2019, J Clin Oncol 2019; 37 (suppl abstr 11586)
  100. **Chiorean EG**, Ritch PS, Zhen DB, Poplin E, George B, Hendifar AE, Dragovich T, Coveler AL, Stoll-D'astice AC, Edwards S, Rosenthal A, Thorsen SM, Hingorani SR. PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma, 2020 ASCO GI Cancers Symposium, J Clin Oncol 2020, 37 (suppl 4; abstr TPS785)
  101. Chang AE, Zhen DB, Radke M, Baker KK, Coveler AL, Wong KM, Pillarisetty VG, Redman MW, Swisher E, **Chiorean EG**. Homologous recombination deficiency (HRD) by BROCA-HR and survival outcomes after surgery for patients with pancreatic adenocarcinoma: A single institution experience, 2020 ASCO GI Cancers Symposium, J Clin Oncol 2020, 37 (suppl 4; abstr 732)
  102. Reni M, Riess H, O'Reilly EM, Tempero M, Reeves J, **Chiorean EG**, George TJ, Scheithauer W, Artru P, Lerch M, Brenner W, Ko YJ, Tabernero J, Van Cutsem E, Philip P, Goldstein D, Berlin J, Biankin A. Concordance between independent and investigator assessment of disease-free survival (DFS) in the APACT trial. ASCO 2020 J Clin Oncol 38: 2020 (suppl; abstr 4618)
  103. Reiss KA, Shah PD, **Chiorean EG**, et al. LODESTAR: A phase II, multicenter open-label study of rucaparib treatment for patients with solid tumors associated with deleterious mutations in homologous recombination repair (HRR) genes. ASCO 2020 abstr
  104. Sharma S, **Chiorean EG**, Alistar AT, et al. Phase I results from a phase 1/2 multi-center study of *nab*-sirolimus combined with mFOLFOX6+bevacizumab as first-line therapy in patients with metastatic colorectal cancer with or without PTEN loss. ASCO 2020 J Clin Oncol 38: 2020 (suppl; abstr e16050)
  105. Sohal D, Duong M, Ahmad SA, Gandhi N, Beg MS, Wang-Gillam A, Wade III JL, **Chiorean EG**, Guthrie KA, Lowy AM, Philip PA, Hochster HS. SWOG S1505: Results of perioperative chemotherapy with mFolfinirinox versus gemcitabine/nab-paclitaxel for resectable pancreatic ductal adenocarcinoma. ASCO 2020 J Clin Oncol 38: 2020 (suppl; abstr 4504)
  106. Wang J, Barve M, **Chiorean EG**, LoRusso P, Courtney K, Qi D, Hoberman M, Sardone M, Dunn V, Chen J, Brooks C, Mughal TI, Bauer TM. Updated results of a phase 1 trial of felezonexor (SL-801), a novel XPO-1 inhibitor in patients with relapsed/refractory solid tumors. ESMO 2020 abstract (poster)
  107. Kim R, Chaves J, Kavan P, Fakih M, Kortmansky JS, Spencer K, Wong L, Tehfe M, Li JJ, Eyring AD, Mayo C, **Chiorean EG**. Pembrolizumab plus mFOLFOX7 or FOLFIRI in patients with metastatic colorectal cancer: updated results from Keynote-651 Cohorts B and D. ESMO 2020 abstract (poster 493P)
  108. **Chiorean EG**, Ritch PS, Zhen DB, Poplin E, George B, Hendifar AE, Dragovich T, Coveler AL, Stoll-D'Astice AC, Edwards S, Rosenthal A, Thorsen SM, Hingorani SR.

- PCRT16-001: Phase II study of PEGPH20 plus pembrolizumab for patients with hyaluronan (HA)-high refractory metastatic pancreatic ductal adenocarcinoma. *J Clin Oncol* 38, 2020 (suppl 4; abstr TPS785)
109. Wong KM, Askovich BI, Ramachandran H, Hensel J, Ottermiller S, Alidina A, Hibbert R, Coveler AL, Thompson JA, **Chiorean EG**. Phase II trial of the CDK4/6 inhibitor abemaciclib in patients with advanced and refractory well differentiated gastroenteropancreatic neuroendocrine tumors (GEP NETs). *J Clin Oncol* 39, 2021 (suppl 3; abstr TPS376)
  110. Sohal D, Duong MT, Chang R, Xue Y, Delman D, Garrido-Laguna I, Mulvihill SJ, Affolter K, Washington MK, Beg MS, Wang-Gillam A, Wade JL III, Gandhi N, Ahmad SA, Lowy AM, **Chiorean EG**, Guthrie KA, Hochster HS, Philip PA, Beatty GL. Immunologic predictors of therapeutic response to neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma in SWOG S1505. *ASCO GI* 2021 abstr (poster)
  111. Diehl A, Hannan LM, **Chiorean EG**. Prognostic value of KRAS and PI3K pathway mutations for advanced pancreatic ductal adenocarcinoma patients. *J Clin Oncol* 39, 2021 (suppl 3; abstr 424); poster
  112. Chung V, Guthrie K, Pishvaian MJ, Lowy AM, **Chiorean EG**, Duong MT, O'Reilly EM, Philip PA. Randomized phase II trial of Olaparib + pembrolizumab vs Olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001. *J Clin Oncol* 2021; 39: suppl 3; abstr TPS447
  113. Byrne KT, Betts CB, Mick R, Sivagnanam S, Bajor DL, Laheru DA, **Chiorean EG**, et al. T cell inflammation in the tumor microenvironment after agonist CD40 antibody: clinical and translational results of a neoadjuvant clinical trial. *AACR* 2021 oral presentation.
  114. Sohal D, Duong MT, Boutin R, Lenchik L, Kim J, Gandhi N, Beg MS, Wang-Gillam A, Wade JL, Guthrie KA, **Chiorean EG**, Ahmad SA, Lowy AM, Hochster HS, Philip PA, Chang VTS. Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505. *J Clin Oncol* 2021; 39; suppl 15, abstr 4131.
  115. Zhen DB, Whittle M, Ritch PS, Hochster HS, Coveler AL, George B, Hendifar AE, Dragovich T, Green S, Dion B, Stoll-D'Astice AC, Lee A, Thorsen SM, Rosenthal A, Hingorani SR, **Chiorean EG**. Phase II study of PEGPH20 plus pembrolizumab for patients (pts) with hyaluronan (HA)-high refractory metastatic pancreatic adenocarcinoma: PCRT16-001. DOI 10.1200/JCO.2022. 40.4\_suppl.576
  116. Soares HP, Guthrie KA, Ahmad SA, Washington MK, Ramnarain BH, Raj NP, Seigel C, Bellasea S, **Chiorean EG**, Dasari A, Strosberg JR, Eng C, Philip PA. Randomized phase II trial of postoperative adjuvant capecitabine and temozolomide versus observation in high-risk pancreatic neuroendocrine tumors: SWOG S2104. DOI 10.1200/ JCO.2022. 40.4suppl.TPS515
  117. Burkard ME, McKean M, Ahnert JR, Mettu NB, Jones JC, Misleh JG, Ma WW, Lim KH, **Chiorean EG**, Pishvaian MJ, Gadgeel SM, McKean HA, Kreider B, Knoerzer D, Groover A, Varterasian ML, Box JA, Emery C, Sullivan RJ. A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations. *J Clin Oncol* 40, 2022 (suppl 16; abstr TPS3172) *ASCO* 2022 poster
  118. Kim RD, Tehfe M, Kavan P, Chaves J, Kortmansky JS, Chen EX, Lieu CH, Wong L, Fakih M, Spencer KR, Zhao Q, Predoiu R, Li C, Carpenter D, Leconte P, **Chiorean EG**. Pembrolizumab plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer in KEYNOTE-651: Long-term follow-up of cohorts B and D. *J Clin Oncol* 40, 2022 (suppl 16; abstr 3521)
  119. Chen EX, Kavan P, Tehfe M, Kortmansky JS, Sawyer MS, **Chiorean EG**, Lieu CH, Polite BN, Wong L, Fakih M, Spencer KR, Chaves J, Li C, Carpenter D, Leconte P,

- Kim RD. Pembrolizumab plus binimetinib with or without chemotherapy for metastatic colorectal cancer: Results from KEYNOTE-651 cohorts A, C, and E. *J Clin Oncol* 40, 2022 (suppl 16; abstr 3573)
120. Borazanci EH, Bahary N, Oberstein PE, Chung V, Skeel RT, **Chiorean EG**, Greenstein AE, Pashova HI, Tudor IC, Mann G. A study of relacorilant in combination with nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. *J Clin Oncol* 40, 2022 (suppl 16; abstr 4140).
121. Zhen DB, Mayerson E, **Chiorean EG**, Burgess EF, Swisher EM, Gay CM, Byers LA, Wistuba II, Mahdi H, Das S, Starr JS, Othus M, Chae YK, Kurzrock R. SWOG S2012: Randomized phase II/III trial of first line platinum/etoposide with or without atezolizumab in patients with poorly differentiated extrapulmonary small cell neuroendocrine carcinomas. *J Clin Oncol* 40, 2022 (suppl 16; abstr TPS4179)
122. **Chiorean EG**, Chapuis A, Coveler AL, et al. Phase I study of autologous transgenic T cells expressing high affinity mesothelin-specific T-cell receptor (TCR; FH-TCR T<sub>MSLN</sub>) in patients with metastatic pancreatic ductal adenocarcinoma. *J Clin Oncol* 41, 2023 (suppl 4; abstr TPS779)
123. Overman MJ, Guthrie KA, Salem ME, Pedersen KA, Kalyan A, Colby S, Fakih M, Gholami S, Gold PJ, **Chiorean EG**, Hochster H, Philip PA. Randomized, phase II selection study of ramucirumab and paclitaxel versus FOLFIRI in refractory small bowel adenocarcinoma: SWOG S1922. *J Clin Oncol* 41, 2023 (suppl 4; abstr TPS784)
124. Reiss KA, Hong SC, Kasi A, O'Reilly EM, Maithel SK, Yao X, Hamilton SR, Boursi B, Pishvaian MJ, Klempner SJ, Domchek SM, Catalano PJ, **Chiorean EG**, Philip PA, O'Dwyer PJ. APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic *BRCA1*, *BRCA2* or *PALB2* mutation—ECOG-ACRIN EA2192. *J Clin Oncol* 41, 2023 (suppl 4; abstr TPS763)
125. Raghav KPS, Guthrie KA, Kopetz S, Tan BR, Denlinger CS, Fakih M, Overman MJ, Dasari A, Corum LR, Hicks LG, Patel M, Esparaz BT, Kazmi SMA, Alluri N, Colby S, Gholami S, Gold PJ, **Chiorean EG**, Hochster HS, Philip PA. A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613. *J Clin Oncol* 41, 2023 (suppl 4; abstr 140)
126. Sameer H. Patel, Sarah Colby, Davendra Sohal, Katherine A Guthrie, Lisa A. Kachnic, E. Gabriela Chiorean, Andrew M. Lowy, Flavio G Rocha, Philip Agop Philip, Syed Ahmad. Chemotherapy dose density and effect on prognosis for patients with resectable pancreas cancer: A secondary analysis of SWOG S1505. *J Clin Oncol* 41, 2023 (suppl 16; abstr 4158) ASCO 2023 poster
127. Ulahannan SV, Spigel DR, Lee MS, Fakih M, Grierson P, Christenson E, **Chiorean EG**, Outlaw DA, Khan G, Atreya CE, Parikh AR, Dayyani F, Spira AI, Kopetz S, Bullock AJ, Li Z, Chen X, Patel H, Hazra S, Strickler JH. Preliminary results from ERAS-007 plus palbociclib in patients with KRAS/ NRAS mutant colorectal cancer or KRASm pancreatic ductal adenocarcinoma in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies. *J Clin Oncol* 41, 2023 (suppl 16; abstr 3558). ASCO 2023 poster
128. Shroff RT, Guthrie KA, Scott AJ, Borad MJ, Goff LW, Matin K, Mahipal A, Kalyan A, Javle MM, Aghajanian C, Tan BR, Cheema PS, Patel AK, Iyer RV, Kelley RK, Thumar JR, El-Khoueiry AB, **Chiorean EG**, Hochster HS, Philip PA. SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. *J Clin Oncol* 41, 2023 (suppl 4; abstr LBA490).

129. Saeed A, Colby S, Oberstein PE, Duda DG, Agarwal R, Figueroa-Moseley C, Vaidya R, Unger JM, Guthrie KA, Rocha F, Senthil M, Safyan R, Wainberg Z, Iqbal S, **Chiorean EG**, Philip A. Philip SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS  $\geq$  1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE). *J Clin Oncol* 42, 2024 (suppl 3; abstr TPS430)
130. Morris VK, Guthrie KA, Kopetz S, Breakstone R, Karasic TB, Hu ZI, Colby S, Fakih M, Gholami S, Gold PJ, **Chiorean EG**, Philip PA. Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, *BRAF*<sup>V600E</sup> metastatic and/or unresectable colorectal cancer: SWOG S2107. *J Clin Oncol* 42, 2024 (suppl 3; abstr TPS234).
131. Safyan R, Colby S, Figueroa-Moseley C, Guthrie K, **Chiorean EG**, Philip P. Diversity of patients enrolled in SWOG gastrointestinal cancers therapeutic trials. *J Clin Oncol* 42, 2024 (suppl 3; abstr 726); ASCO GI 2024 poster
132. King G, Berg R, Yilma B, Stoppler M, Hsieh R, Safyan R, Zhen D, Coveler A, Cohen S, Shankaran V, **Chiorean EG**, Harris W. Genomic and immune landscape of biliary tract cancers with *ARID1A*, *PBRM1*, and *BAP1* alterations. *J Clin Oncol* 42, 2024 (suppl 3; abstr 557) poster
133. Sahin I, Chakrabarti S, Hsieh R, Bruno B, Selfridge JE, Gorantla V, Thomas R, Rhee J, Tatsuoka C, Bajor D, Mahipal A, **Chiorean EG**, Tejani M, Saeed A. Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01. *J Clin Oncol* 42, 2024 (suppl 3; abstr TPS238)
134. Zhen DB, Moseley A, **Chiorean EG**, Burgess EF, Swisher EM, Gay CM, Byers LA, Wistuba II, Mahdi H, Starr JS, Othus M, Chae YK, Kurzrock R. SWOG S2012: Randomized phase II/III trial of first line platinum /etoposide with or without atezolizumab in patients with advanced or metastatic poorly differentiated extrapulmonary neuroendocrine carcinomas. *J Clin Oncol* 42, 2024 (suppl 16; abstr TPS4201) ASCO 2024 poster.
135. Parikh AR, **Chiorean EG**, Atreya CE, Zheng L, Kopetz S, Spira AI, Spigel DR, Cui Y, Osgood R, Tran R, Morris SR, Ulahannan SV. Updated results from ERAS-007 plus encorafenib and cetuximab in patients with EC-naïve metastatic BRAF V600E colorectal cancer in the phase 1b/2 HERKULES-3 study. *J Clin Oncol* 42, 2024 (suppl 16; abstr 3517). ASCO 2024 Rapid Oral Presentation.
136. Mitchell S, Khan B, Payumo F, **Chiorean EG**, Gahvari Z, Hecht JR, Hurwitz ME, Leidner R, Lenz HJ, Pelster M, Puneekar SR, Schoenfeld AJ, Zhao D, Vallaster MP, Nagorsen D. AFNT-211: A phase 1 study of autologous CD4+ and CD8+ T cells engineered to express a high avidity HLA-A\*11:01-restricted, KRAS G12V-specific, transgenic TCR, a CD8a/b coreceptor, and a FAS41BB switch receptor in patients with advanced/metastatic solid tumors. *J Clin Oncol* 42, 2024 (suppl 16; abstr TPS8650). ASCO 2024 poster.
137. Safyan RA, Redman MW, Coveler AL, Cohen SA, Lee S, Yeung C, Schmitt T, Chapuis A, Greenberg PD, **Chiorean EG**. Phase I study of autologous CD8+ and CD4+ transgenic T cells expressing high affinity KRAS G12V mutation-specific T cell receptors (FH-A11KRASG12V-TCR) in patients with metastatic pancreatic, colorectal, and non-small cell lung cancers with KRAS G12V mutations. *J Clin Oncol* 43, 2025 (suppl 4; abstr TPS792); ASCO GI Symposium 2025; poster
138. Chung V, Guthrie KA, Pishvaian MJ, Lowy AM, Sohal D, Reiss KA, Sanford NN, Allegra C, Colby S, O'Reilly EM, **Chiorean EG**, Philip PA. Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 mutations: SWOG S2001 NCT04548752. *J Clin Oncol* 43, 2025 (suppl 4; abstr TPS793). ASCO GI Symposium 2025 poster.

139. Sahin IH, Hsieh RW, Gorantla V, Cohen SA, Rhee JC, Safyan RA, Tatsuoka C, **Chiorean EG**, Tejani MA, Benson AB, Boland PM, Kim RD, Saeed A. Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01. *J Clin Oncol* 43, 2025 (suppl 4; abstr TPS313). ASCO GI 2025; poster.
140. King GT, Baker KK, Coveler AL, Safyan RA, Wong K, Shankaran V, Zhen DB, Lee HH, Hensel J, Hibbert R, Durm GA, Redman MW, Pritchard C, Shahda S, **Chiorean EG**. Phase I/Ib study of afatinib with capecitabine in patients with refractory solid tumors and pancreaticobiliary cancers. *J Clin Oncol* 43, 2025 (suppl 4; abstr 594). ASCO GI 2025; poster.
141. Huang AH, Hsieh RW, Lu C, Sahin IH, King GT, Safyan RA, Cohen SA, Zhen DB, Shankaran V, Harris WP, Coveler AL, Lin PJ, Malhotra J, Forbes V, **Chiorean EG**, Lee GY. Rechallenge with epidermal growth factor receptor inhibitors for metastatic colorectal cancer: A systematic review and meta-analysis. *J Clin Oncol* 43, 2025 (suppl 4; abstr 184). ASCO GI 2025, poster.

## 17. INVITED TALKS, INCLUDING CME PRESENTATIONS

### A. NATIONAL/INTERNATIONAL

- 2001 BCR/ABL Alters the Function of NK Cells. Oral presentation, International Society of Hematology, Tokyo, Japan
- 2006 Novel Treatments in Pancreatic Cancer; 11<sup>th</sup> Annual Distinguished Lecture Series / New Perspectives in Cancer Research, Van Andle Research Institute, Grand Rapids, MI
- 2008 Phase 1 Study of CT-322, first adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients with advanced solid tumors. Oral presentation ASCO, Chicago, IL.
- 2009 Annual NCCTG (North Central Cancer Treatment Group) Patient Advocate Symposium "GI Clinical Trials-Hoosier Oncology Group", Rochester, MN
- 2010 Ohio State University Phase 1/2 Clinical Trials Special Seminar: Colorectal Cancer, Columbus, OH
- 2010 Phase II trial of neoadjuvant capecitabine with irinotecan followed by capecitabine-based chemoradiotherapy for patients with locally advanced rectal cancer: A Hoosier Oncology Group Study. Oral Presentation, ASTRO Meeting, San Diego, CA.
- 2011 Community Debates in Colorectal Cancer, Provena Medical Center, Urbana, IL
- 2011 Virginia Mason Cancer Institute Seminar: "Colorectal Cancer, Biology and Treatment Updates", Seattle, WA
- 2011 Fred Hutchinson Cancer Research Center Grand Rounds "Colorectal Cancer: How a Complex Biology Affects Clinical Research", Seattle, WA
- 2011 Phase I study of TAK-285, an investigational HER2/EGFR inhibitor, in patients with advanced cancer: Updated results and assessment of human CSF distribution. Poster Discussion. ASCO, Chicago, IL
- 2011 Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies. Poster Discussion, ASCO, Chicago, IL
- 2011 Best of ASCO-Slovakia: Gastrointestinal Cancers Non-colorectal, Bratislava, Slovakia
- 2011 Experiences and Insight on CA-046: Phase III trial of Gemcitabine and Nanoparticle-Bound Paclitaxel in Metastatic Pancreatic Cancer; an Investigator's Perspective; Seville, Spain
- 2011 Community Debates in Colorectal Cancer, Provena Medical Center, Urbana, IL
- 2012 A randomized crossover phase 2 study of the safety and efficacy of two dose levels of TH-302 in combination with gemcitabine compared with gemcitabine alone in

- previously untreated patients with locally advanced unresectable or metastatic pancreatic adenocarcinoma. Oral Presentation. AACR, Chicago, IL
- 2012 A phase 1, open-label, dose-escalation study of oral mammalian target of rapamycin (TORC1/2) inhibitor MLN0128 (INK128) administered by intermittent dosing regimens in patients with advanced malignancies. Oral Presentation. AACR, Chicago, IL
- 2012 Pharmacokinetic study of enzastaurin in cancer patients with varying degrees of hepatic dysfunction. Oral Presentation. EORTC-NCI-AACR, Dublin, Ireland
- 2013 American Association of Cancer Research (AACR) Clinical Trials Symposium: Clinical Pharmacology of Novel Agents in Solid Tumors Discussant: "A phase 1 study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel in patients with refractory solid tumors", Washington, D.C.
- 2013 American Society of Clinical Oncology (ASCO) Developmental Therapeutics-Clinical Pharmacology and Experimental Therapeutics Poster Discussant, Chicago, IL
- 2013 Best of ASCO-Los Angeles: Developmental Therapeutics, Los Angeles, CA
- 2013 Randomized phase III study of weekly nab-paclitaxel plus gemcitabine vs gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas. Oral Presentation. ASCO, Chicago, IL
- 2013 Algenpantucel-1 immunotherapy for pancreatic cancer induces anti-mesothelin antibody titers that positively correlate with improved overall survival. Oral Presentation. ASCO, Chicago, IL
- 2013 Phase I study of everolimus and ganitumab in patients with advanced solid tumors. Poster Discussion, ASCO, Chicago, IL
- 2013 A phase I first-in-human study of REGN421, a fully-human Delta-like Ligand 4 monoclonal antibody, in patients with advanced solid tumors. Oral Presentation. ASCO, Chicago, IL
- 2014 9<sup>th</sup> Annual State of the Art Treatment of Gastrointestinal Cancers: Colorectal Cancer: Role of Molecular Tests in the Era of Personalized Medicine, Detroit, MI
- 2014 32<sup>nd</sup> National Congress of the Society of Mexican Oncology (SMeO): Novel Treatments for Pancreatic Cancer, Ixtapa-Zihuatanejo, Mexico
- 2015 Best of ASCO-Romania: Gastrointestinal Cancers, Cluj-Napoca, Romania
- 2015 UCLA Sylmar Medical Center Grand Rounds: The evolving treatment landscape for pancreatic cancer: clinical advances for you and your patient, Sylmar, CA
- 2015 3<sup>rd</sup> International Pancreas Cancer Forum/Workshop: panel discussion on treatments for pancreatic cancer, Milano, Italy
- 2016 ASCO Educational Session (Presenter and Chair): Localized Pancreatic Cancer: Multidisciplinary Management with Incorporation of ASCO Guidelines, Chicago, IL
- 2016 Comprehensive Oncology Review Course (UW/SCCA): Gastrointestinal and Pancreatico-Biliary Cancers, Honolulu, HI
- 2016 FDA Pancreas Cancer Symposium: Are we ready for biomarker-driven clinical trials in pancreatic cancer? White Oak, MD
- 2016 Mayo Clinic Pancreatic Cancer Conference: Targeting Molecular Subsets in Pancreatic Cancer, Phoenix, AZ
- 2017 Translational Symposium of Precision Medicine against Cancer: STOP Cancer: Contemporary Treatment for Pancreatic Cancer, Bucharest, Romania
- 2017 ASCO, Educational Session: Locally Advanced Pancreatic Cancer: Is There a Role for Radiotherapy? ASCO 2017 Meeting, Chicago, IL
- 2017 ASCO, GI Non-Colorectal Cancers Oral Abstracts Discussant: Old Friends and New Beginnings in Pancreatico-Biliary Cancers, ASCO 2017 Meeting, Chicago, IL
- 2017 Best of ASCO-Romania: Gastrointestinal Cancers, Cluj-Napoca, Romania

- 2017 Gianaris Memorial Lecture in Pancreatic Cancer: Update in Pancreatic Cancer Translational Research, Indiana University Simon Cancer Center, Indianapolis, IN
- 2017 Research to Practice “Cases from the community-clinical investigators provide their perspectives on emerging research and actual patients with gastrointestinal cancers”, Chicago, IL
- 2017 Expert Practice in Pancreatic Cancer, Keynote Lecture: Targeting the tumor microenvironment in pancreatic cancer, Budapest, Hungary
- 2017 Society of Nuclear Medicine and Molecular Imaging (SNMMI), Advances in Nuclear Imaging and Therapy Neuroendocrine Tumors: Neuroendocrine cancers: the Oncologist Perspective, Seattle, WA
- 2018 ASCO SITC: Using Genomic Profiling for Tumor Immunotherapy - New Paradigms for the Treatment of Microsatellite Instability High Solid Tumors “Implications of Pembrolizumab Approval for MSI-High Solid Tumors”, San Francisco, CA
- 2018 ASCO-SITC Trainee and Early-Career Networking Luncheon: “Taking Care of the Immunotherapy Patient”, San Francisco, CA
- 2018 Best of ASCO Chicago: GI (non-CRC) cancers updates, Chicago, IL
- 2018 ASCO: Highlights of the Day GI Cancers (non-CRC), Chicago, IL
- 2018 Indiana University ASCO 2018 Review: GI Cancers Review Panel
- 2018 ASCO Advantage: Oncology Education for Industry Professionals: Pancreatic Cancer One-Day Course, Alexandria, VA
- 2018 Visiting Professor Lecture: Pancreas Cancer Clinical and Translational Research, Halozyme Pharmaceuticals, San Diego, CA
- 2018 Denali Oncology Conference: Pancreatic Cancer: Clinical Standards and Research, Kodiak, AK
- 2018 Denali Oncology Conference: Updates in the Management of Hepato-Biliary Cancers, Kodiak, AK
- 2018 Pancreatic Cancer Update-an enduring audio, video, podcast, web and mobile interview series for medical oncologists and other GI cancer professionals: 2018 Edition - Neil Love Research to Practice
- 2019 Randomized Phase II Study of 2nd Line Modified FOLFIRI with PARP Inhibitor ABT 888 (Veliparib) vs FOLFIRI in Metastatic Pancreatic Cancer: SWOG S1513. Poster Discussion. ASCO, Chicago, IL
- 2019 The Role of Focused Ultrasound in Pancreatic Cancer- Panel Discussion of Burning Questions, Rockville, MD
- 2019 Translational Symposium of Precision Medicine against Cancer STOP Cancer, Bucharest, Romania
- 2019 Best of ASCO Romania: Gastrointestinal Cancers, Cluj-Napoca, Romania
- 2019 ASTRO Annual Meeting: Challenging Cases in GI Malignancies, Chicago, IL
- 2019 Pancreatic Cancer Focused Ultrasound Foundation: Panel Discussion- future directions for focused ultrasound in pancreatic cancer, Rockville, MD
- 2020 Best of ASCO Romania: Gastrointestinal Cancers, Cluj-Napoca, Romania
- 2020 Translational Symposium of Precision Medicine against Cancer STOP Cancer: Pancreas Cancer Updates, Bucharest, Romania
- 2020 International Society of Gastrointestinal Oncology (ISGIO): Should all patients with pancreas cancer undergo genetic testing?
- 2020 Society of Medical Oncology, Romania: Metastatic Colorectal Cancer: What’s New in 2020?
- 2020 Society of Abdominal Radiology: Treatment and Translational Updates in Pancreatic Cancer; virtual
- 2021 Pancreatic Cancer Action Network Precision Promise Consortium: Targeting Mesothelin with TCR T cells for Pancreatic Cancer

- 2021 National Pancreas Foundation, Fellows Symposium: Novel Therapies for Pancreatic Cancer
- 2021 Great Debates and Updates in Gastrointestinal Malignancies:  
Debate: First Line Immunotherapy in MSI-High Colorectal Cancer: Single Agent  
Debate: Sequencing of Therapy in Non-Operative Management of Rectal Cancer:  
Chemotherapy First  
Challenging Cases in Hepatobiliary Cancers
- 2021 International Association of Surgeons, Gastroenterologists and Oncologists (IASGO); IX. Onco Surgery Days e-Symposium: Molecular Targets and Targeted Therapeutics for Pancreatic Cancer, Istanbul, Turkey
- 2021 T cell inflammation in the tumor microenvironment after agonist CD40 antibody: clinical and translational results of a neoadjuvant clinical trial. Oral Presentation. AACR, virtual
- 2021 Best of ASCO Romania: Gastrointestinal Cancers, Cluj Napoca, Romania
- 2021 ASCO eLearning Tumor Board: Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
- 2021 Translational Symposium of Precision Medicine against Cancer STOP Cancer: Molecular Targets in Pancreatic Cancer, Bucharest, Romania
- 2021 NCCN 2021-2022 Monthly Oncology Tumor Board Series: Pancreatic Cancer, a Multidisciplinary Approach to Individualized Patient Care.
- 2021 Romanian National Oncology Congress: Systemic Treatments for Metastatic Pancreatic Cancer, Poiana Brasov, Romania
- 2022 University of Cincinnati Cancer Center, Multidisciplinary Management of GI Cancers: Keynote Address: Clinical and Translational Research Updates in Pancreatic Cancer
- 2022 ASCO Plenary Series: First data for sotorasib in patients with pancreatic cancer with KRASp.G12C mutation: a phase I/II study evaluating efficacy and safety. Discussant
- 2022 STOP Cancer Educational Symposium: Updates in the Treatment of Pancreas, Hepatocellular and Biliary Tract Cancers, Virtual Oncology Fellows Series, Romania
- 2022 NCCN Virtual Annual Conference: Pancreatic Adenocarcinoma: Emerging Systemic Therapy Options, moderator
- 2022 Best of ASCO Romania –Gastrointestinal Malignancies, Discussion, Cluj-Napoca, Romania
- 2022 Best of ASCO Romania – Educational Symposium: GI Malignancies- A Patient’s Journey, Cluj-Napoca, Romania
- 2022 STOP Cancer Translational Research Symposium: Molecular and Immune Targets for Pancreatic Cancer, Bucharest, Romania
- 2022 National Society of Medical Oncology: KRAS, a Treatable Target in Colorectal Cancer, Poiana Brasov, Romania
- 2022 International Association of Surgeons, Gastroenterologists and Oncologists (IASGO); 33<sup>rd</sup> World Congress: Perioperative Therapy for Pancreatic Cancer, Istanbul, Turkey
- 2022 International Association of Surgeons, Gastroenterologists and Oncologists (IASGO); 33<sup>rd</sup> World Congress: Clinical and Translational Updates in Pancreatic Cancer, Istanbul, Turkey
- 2022 Atlantic Health System GI Symposium: Updates in Pancreatic Cancer. Virtual
- 2022 Cases from Kampala Joint Clinical Care Conference: Pancreatic Cancer; FHCC and Uganda Cancer Institute; virtual
- 2026 SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers. Oral Presentation. ASCO GI Symposium, San Francisco, CA

- 2023 ASCO Plenary Series: Moderator: Zolbetuximab + CAPOX in 1L claudin-18.2+ (CLDN18.2+)/HER2- locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: primary phase 3 results from GLOW. Virtual
- 2023 STOP Cancer Translational Research Symposium: Precision Oncology in Cholangiocarcinomas, Bucharest, Romania
- 2023 Oakland University/William Beaumont Hospital Grand Rounds: Precision Medicine in Pancreatic Cancer. Royal Oak, MI, Virtual
- 2023 International Association of Surgeons, Gastroenterologists and Oncologists (IASGO); 34<sup>th</sup> World Congress: New Approaches for Gastroenteropancreatic Neuroendocrine Tumors, Verona, Italy
- 2023 IASGO; 34<sup>th</sup> World Congress: Critical Review of Perioperative and Adjuvant Clinical Trials for Pancreatic Cancer, Verona, Italy
- 2023 GI Oncology Symposium: Adoptive Immunotherapy Targeting Mesothelin in Pancreatic Cancer, Bermuda
- 2023 GI Oncology Symposium: Targeting the CXCR4/CXCL12 Axis in Combination with Immune Checkpoint Inhibition for Neoadjuvant Therapy in Pancreatic Cancer, Bermuda
- 2023 12<sup>th</sup> Franco-Romanian Symposium on Digestive Oncology, OncoDigest: ASCO ESMO 2023 Non-Colorectal Cancers Update, Sinaia, Romania
- 2023 American Molecular Pathology Symposium. NGS testing for gene fusions in solid tumors. Salt Lake City, UT
- 2023 SWOG Latin America - Cancers Associated with Infection: Liver and Biliary Cancers, Bogota, Colombia
- 2024 9<sup>th</sup> Annual School of Gastrointestinal Oncology: Precision Medicine in GI Non-Colorectal Cancers, Los Angeles, CA
- 2024 STOP Cancer Series: Update in Pancreatic Cancer (virtual) Romania
- 2024 ASCO Annual Meeting, Education Session: Importance of Multidisciplinary Care for Individuals with Pancreatic Cancer, Chicago, IL
- 2024 Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients with EC-naïve metastatic BRAF V600E colorectal cancer in the phase 1b/2 HERKULES-3 study. Rapid Oral Presentation. ASCO 2024, Chicago, IL
- 2024 Pittsburgh Annual Oncology Symposium: Experts and Evidence 2024; Molecular Targeting of Pancreatic Cancer, Pittsburgh, PA
- 2024 Best of ASCO Romania: Gastrointestinal Cancers, Cluj-Napoca, Romania
- 2024 ASTRO Annual Meeting, Education Session: Role of Systemic Therapy - Targeted Therapy and Immunotherapy in Pancreatic Cancer and Extrahepatic Cholangiocarcinoma, Washington, D.C
- 2024 International Association of Surgeons, Gastroenterologists and Oncologists (IASGO); 35<sup>th</sup> World Congress: Pancreatic Cancer - Updates on Molecular Targets and Clinical Trials Development with Targeted Therapies, Cairo, Egypt
- 2024 IASGO 35<sup>th</sup> Congress, Pancreatic Cancer Section, Co-Chair, Cairo, Egypt
- 2024 Instituto Nacional de Enfermedades Neoplásicas (INEN) – SWOG Latin America, A Clinical and Translational Trial Conference: Research Landscape for Gastrointestinal Cancers in the US, Lima, Peru
- 2024 American Pancreas Association (APA)/Japanese Pancreas Society (JPS)/Chinese Association of Pancreatology (CAP)/International Association of Pancreatology (IAP): Current Landscape of KRAS Inhibitors in Pancreatic Cancer, Maui, HI
- 2025 Molecular Testing and Personalized Strategies in Pancreatic Cancer: Targeting NRG1 and Rare Drivers with an Optimized Approach, PER-OncoLive ASCO GI Symposium, San Francisco, CA

**B. REGIONAL**

- 2006 Indiana University Cancer Center Grand Rounds: Pancreatic Cancer: Novel Therapies and “Attitudes”, Indianapolis, IN
- 2006 Pancreatic Cancer Update in Diagnosis and Treatment; Grand Rounds Columbus Regional Hospital, Columbus, IN
- 2006 Metastatic Pancreatic Cancer Update; GI Oncology Symposium – the Indiana University Multidisciplinary Approach, Indianapolis, IN
- 2007 New Challenges in Treatment of Early and Metastatic Colorectal Cancer; 29<sup>th</sup> Annual Oncology Symposium on Colorectal Cancer, Vincennes, IN
- 2007 Metastatic Colorectal Cancer Update; GI Oncology Symposium – the Indiana University Multidisciplinary Approach, Indianapolis, IN
- 2008 Colorectal Cancer – Case Presentations, Indianapolis, IN
- 2008 Colorectal Cancer – Case Presentations, Bloomington, IN
- 2008 Revising Cancer Management Approaches in 2008 - Educational Seminar: “VEGF Application and Side Effects Management”, Indiana Community Cancer Care Foundation, Indianapolis, IN
- 2008 Indiana University Cancer Center Grand Rounds: Schwartz Center Rounds: “The Over-Involved Spouse”, Indianapolis, IN
- 2009 Indiana University ASCO 2009 Review: GI-Non-Colorectal Cancers Update, Indianapolis, IN
- 2009 Grand Rounds: Pancreatic Cancer Update, Reid Hospital, Richmond, IN
- 2010 Indiana University ASCO 2010 Review: GI-Non-Colorectal Cancers Update, Indianapolis, IN
- 2011 Review and Interpretation of the 2011 ASCO meeting: GI Non-Colorectal Cancers, Indianapolis, IN
- 2012 UW/SCCA Comprehensive Oncology Review Course: Hepatobiliary Malignancies, Seattle, WA
- 2012 SCCA Outreach Community Series: Update in the Treatment of Pancreatic Cancer, Bellingham, WA
- 2012 SCCA Outreach Community Series: Update in the Treatment of Pancreatic Cancer, Bremerton, WA
- 2013 SCCA Outreach- Colorectal Cancer Journal Club, Wenatchee, WA
- 2013 SCCA Outreach: Pancreas Cancer Updates
- 2013 UW/SCCA Comprehensive Oncology Review Course: Pancreas Cancer: Treatment Updates, Seattle, WA
- 2013 Emerging Therapies in Colorectal Cancer, Tacoma Multicare Regional Cancer Center, Tacoma, WA
- 2013 Update in Pancreas Cancer Treatment, SCCA Network-Wenatchee, WA
- 2014 UW/SCCA/FHCRC GI Oncology Symposium 2014: Research to Practice: Pathways, Targets and Pipeline Drugs for GI Cancers, Seattle, WA
- 2014 Breakthroughs in Solid Tumors Oncology Symposium: Novel Treatments in Colorectal and Pancreatic Cancers, Seattle, WA
- 2014 UW/SCCA Comprehensive Oncology Review Course: Pancreas Cancer: Treatment Updates, Seattle, WA
- 2015 Virginia Mason GI Potpourri: GI Malignancies: Treatment and Care Update, Seattle, WA
- 2015 SCCA Evergreen-Halvorson Cancer Center Grand Rounds: New research advances in colorectal cancers, Kirkland, WA
- 2016 UW/FHCRC/SCCA Advances and Current Management of GI Cancers: Pancreas Cancer Case Presentations, Seattle, WA
- 2016 Comprehensive Oncology Review Course (SCCA): Colorectal Cancer, Honolulu, HI

- 2016 Comprehensive Oncology Review Course (SCCA): Esophageal/ Gastric Cancer, Honolulu, HI
- 2016 Comprehensive Oncology Review Course (SCCA): Hepatobiliary Cancers, Honolulu, HI
- 2016 Comprehensive Oncology Review Course (SCCA): Pancreatic Cancer, Honolulu, HI
- 2016 Comprehensive Oncology Review Course (SCCA): Neuroendocrine Cancers, Honolulu, HI
- 2016 UW/SCCA Comprehensive Oncology Board Review Course: Pancreas Cancer: Treatment Updates; Seattle, WA
- 2016 Virginia Mason Pancreatic Cancer Symposium: Biomarkers and novel therapies in pancreatic cancer: moving forward, Seattle, WA
- 2017 UW/SCCA Comprehensive Oncology Board Review Course: Pancreas Cancer, Seattle, WA
- 2018 UW/SCCA Comprehensive Oncology Board Review Course: Pancreas Cancer, Seattle, WA
- 2019 UW/SCCA Comprehensive Oncology Board Review Course: Pancreas Cancer, Seattle, WA
- 2019 Onc-Live: Treatment of Localized Pancreatic Cancer, Seattle WA
- 2020 UW/SCCA Comprehensive Oncology Board Review Course: Pancreas Cancer, Seattle, WA
- 2021 UW/SCCA Comprehensive Oncology Board Review Course: Pancreas Cancer, Seattle, WA
- 2021 OnLive Institutional Updates: Pancreatic Cancer Treatment Updates and Clinical Trials
- 2024 Pacific Northwest Society of Pathologists: Optimizing Pathology Reports to Meet Oncologists Needs, Seattle, WA

### **C. LOCAL**

- 2014 Core Teaching Resident Lecture: Update in colorectal cancer, UW, Seattle
- 2015 Core Teaching Resident Conference: GI Malignancies with Emphasis on Colon Cancer, UW, Seattle
- 2015 Fellows' Clinical Trials and Biostatistics Lecture: Phase I clinical trials: an Investigator's Perspective, FHRC, Seattle
- 2015 Fellows' Clinical Trials and Biostatistics Lecture: Phase II clinical trials: an Investigator's Perspective, FHRC, Seattle
- 2015 Radiation Oncology Resident Lecture: New Research Advances in Colorectal Cancers, UW, Seattle
- 2015 Hematology/Oncology Fellow's Lecture Series: Pancreas and Neuroendocrine Tumors, FHRC, Seattle
- 2016 Hematology/Oncology Fellow's Lecture Series: Pancreas and Neuroendocrine Tumors, FHRC, Seattle
- 2016 Solid Tumor Translational Research (STTR) Pancreas Cancer Research Forum: Pancreas cancer: role of biomarkers in clinical trials, Seattle
- 2016 FHRC Grand Rounds: Biomarkers, Targets and Getting Ready for Precision Medicine in Pancreatic Cancer, Seattle, WA
- 2017 Hematology/Oncology Fellow's Lecture Series: Pancreas and Neuroendocrine Tumors, FHRC, Seattle
- 2018 STTR Pancreatic Cancer Research Conference: Targeting the Tumor Microenvironment in Pancreatic Cancer
- 2018 Hematology/Oncology Fellows' Lecture Series: Pancreas Cancer, FHRC
- 2019 FHRC Grand Rounds: Real and Elusive Targets in Pancreatic Cancer, Seattle, WA

- 2019 Hematology/Oncology Fellows' Lecture Series: Pancreas Cancer, FHCRC
- 2020 Hematology/Oncology Fellow's Lecture Series: Pancreas and Neuroendocrine Tumors, FHCRC, Seattle
- 2020 STTR Pancreas Cancer Research Conference: Targeting Mesothelin with Transgenic TCR-T Cells in Pancreatic Cancer, FHCRC
- 2021 Hematology/Oncology Fellow's Lecture Series: Pancreas and Neuroendocrine Tumors, FHCRC, Seattle
- 2022 Hematology/Oncology Fellow's Lecture Series: Pancreas and Neuroendocrine Tumors, FHCC, Seattle
- 2023 Science Says: Where Science and Care Meet; Updates on the GI Oncology Program and Precision Medicine for Pancreatic Cancer at FHCC
- 2023 STTR Pancreas Cancer Research Conference: Molecular and Immune Targets in Pancreatic Cancer
- 2023 FHCC Pancreas Cancer Lunch and Learn: Pancreas Cancer- Novel Strategies in Research
- 2025 FHCC Pancreas Club: Targeting DDR defects and KRAS Wild Type Pancreatic Cancer